<!DOCTYPE html>


<style>
    body{
  background: #18181B;
}

.main{
  font-family: "Noto Sans", ui-sans-serif, system-ui, -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol", "Noto Color Emoji";
  color: #FDFDFD;
}

h1 {
  font-size: 2.5rem;
  color: white;
}

h3 {
  font-size: 1.5rem;
  background: #0c087c;
  padding: 10px;
  margin: 0px;
  border: 1px solid #6b7280;}

.extended-title{
  width:100%;
}

#gsk-overview{
  display:flex;
}

h4 {
  font-size: 1rem;
  background: #27272A;
  padding: 10px;
  margin: 0px;
  border-bottom: 1px solid #6b7280;
}

h2 {
  font-size: 1.5rem;
  margin-top: 3px;
  color:#000000;
}

.header{
  display: flex;
  justify-content: center;
  align-items: center;
}
.header > * {
  margin-inline: 20px;
}

.flex-row {
  display: flex;
  flex-direction: row;
  padding:10px;
  border: 1px solid #27272A;
}

.flex-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
}

progress[value] {
  --background: #6D6D6D;
  -webkit-appearance: none;
  -moz-appearance: none;
  appearance: none;
  border: none;
  height: 4px;
  margin: 0 10px;
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-bar {
  border-radius: 10em;
  background: var(--background);
}

progress[value]::-webkit-progress-value {
  border-radius: 10em;
  background: var(--color);
}

progress[value]::-moz-progress-bar {
  border-radius: 10em;
  background: var(--color);
}

label {
  font-size: 20px;
  font-weight: bold;
  display: block;
  margin: 20px 0;
}

.tab {
  overflow: hidden;
  border: 1px solid #27272A;
  background-color: #27272A;
}

.tab button {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size:1.2rem;
}

.tab div {
  background-color: inherit;
  float: left;
  border: none;
  outline: none;
  cursor: pointer;
  padding: 14px 16px;
  transition: 0.3s;
  color: #ffffff;
  font-size: 1.2rem;
}

.tab button:hover {
  background-color: #18181B;
}

.tab-title{
  font-size: 1.5rem;
  font-weight: bold;
  margin-bottom:-5px;
}

.tab button.active {
  background-color: #18181B;
  border-top: 1px solid #6b7280;
  border-bottom: 1px solid #18181B;
  border-left: 1px solid #6b7280;
  border-right: 1px solid #6b7280;
}

.tabcontent {
  display: none;
  padding: 6px 12px;
  background: #18181B;
  border: 1px solid #27272A;
  border-top: 1px solid #6b7280;
  margin-top: -2px;
}

#gsk-advice {
  display: flex;
  justify-content: center;
}

#gsk-metrics{
  width:100%;
}

#recommendation {
  margin-top: 20px;
  padding: 20px;
  border-radius: 10px;
  background-color: #e1ce86;
  color: #27272A;
  width:95%;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  font-size: 12pt;
}

.separator {
  margin: 20px 0;
}

.separator-border {
  margin: 20px 0;
  border-bottom: 1px solid #6b7280;
}

#gsk-rag{
  margin: 32px 28px;
  padding: 12px 24px;
  background-color: #111516;
}

.section-container {
  margin-bottom: 32px;
}

  .components-container {
    display: flex;
    flex-flow: row wrap;
    align-items: flex-start;
    gap: 0 32px;
  }

    .component-card {
      background-color: #14191B;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      margin-top: 32px;
      flex-grow: 1;
    }

    .component-title {
      font-size: 12px;
      font-weight: 500;
      color: #B1B1B1;
      padding-bottom: 8px;
    }

    .component-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
    }
      
      .text-green {
        color: #04B543;
      }
      
      .text-orange {
        color: #E76E0F;
      }
      
      .text-red {
        color: #EA3829;
      }

      .tooltip {
        position: relative;
        display: inline-block;
      }

      .tooltip .tooltiptext {
        visibility: hidden;
        width: 120px;
        background-color: #464646;
        color: #E6E6E6;
        text-align: center;
        border-radius: 6px;
        position: absolute;
        z-index: 1;
        top: 150%;
        left: 50%;
        margin-left: -60px;
        font-size: 12px;
        padding: 12px;
      }
      
      .tooltip .tooltiptext::after {
        content: "";
        position: absolute;
        bottom: 100%;
        left: 50%;
        margin-left: -5px;
        border-width: 5px;
        border-style: solid;
        border-color: transparent transparent black transparent;
      }
      
      .tooltip:hover .tooltiptext {
        visibility: visible;
      }

    .overall-card {
      background-color: #026836;
      border-radius: 16px;
      padding: 28px 32px 32px 32px;
      display: flex;
      flex-flow: column;
      align-items: center;
      justify-content: center;
      margin-top: 32px;
      flex-grow: 1;
    }
  
    .overall-title {
      font-size: 12px;
      font-weight: 500;
      color: #E6E6E6;
      padding: 14px 0 8px 0;
      text-transform: uppercase;
     }
  
    .overall-value {
      font-size: 32px;
      font-weight: 500;
      padding-bottom: 12px;
      color: #E6E6E6;
    }

.section-title {
  font-size: 12px;
  color: #B1B1B1;
  margin-bottom: 20px;
  text-align: left;
  width: 100%;
}

.section-content {
  color: #E6E6E6;
  font-size: 20px;
  line-height: 1.5;
}

.section-card {
  background-color: #14191B;
  border-radius: 16px;
  padding: 28px 32px 32px 32px;
  display: flex;
  flex-flow: column;
  align-items: center;
}

.correctness-indicator{
  padding: 20px;
  border-radius: 50px;
  font-size: 16pt;
  box-shadow: 0 4px 8px 0 #000000, 0 6px 20px 0 #000000;
  text-align: center;
}

.metric-title{
  margin: -2px;
  border-bottom: none;
}

.hist-row {
  display: flex;
  flex-direction: row;
  padding: 10px;
  justify-content: space-around;
  width: 85%;
}

.hist-row>div {
  flex: auto;
  box-sizing: border-box;
  display: flex;
  flex-direction: column;
  justify-content: center;
  align-items: center;
  padding-left: 1%;
  padding-right: 1%;
}

.tab-row{
  display: flex;
  flex-direction: column;
  align-items: center;
}

#component-table{
  width:50%;
  margin-top: 10px;
}

.green{
  background-color: #0a980a;
}

.orange {
  background-color: #e5b62a;
}

.red {
  background-color: #ba0e0e;
}

.progress-green {
  --color: #04B543;
}

.progress-orange {
  --color: #E76E0F;
}

.progress-red {
  --color: #EA3829;
}

.corr-plot{
  flex: 1;
  padding-left: 2%;
}

.tooltip-text {
  position: absolute;
  display: none;
  visibility: hidden;
  z-index: 1;
  top: 100%;
  left: 0%;
  width: 100%;
  color: white;
  font-size: 12px;
  background-color: #2d3d4c;
  border-radius: 10px;
  padding: 10px 15px 10px 15px;
}

#fade {
  opacity: 1;
  transition: opacity 0.5s;
}

#delay {
  opacity: 0;
  transition: opacity 0.2s;
  transition-delay: 1s;
}

td {
  position: relative;
}

tr:hover .tooltip-text {
  display: block;
  visibility: visible;
}

.tr:hover #fade {
  opacity: 1;
}

.tr:hover #delay {
  opacity: 1;
}

.callout {
  padding: 0.5rem 1rem 0.5rem 3rem;
  background: #D9EDF9;
  border: 3px solid #0088D1;
  color: #272eb5;
  position: relative;
  max-width: 40rem;
  border-radius: 10px;
  margin-top: 10%;
  font-size: 11pt;
}

.callout-icon {
  content: "";

  /* SVG via a data URI! */
  background-size: cover;
  width: 1.5rem;
  height: 1.5rem;
  display: block;
  position: absolute;
  left: 0.9rem;
  top: 1.1rem;
}

.callout-icon svg{
  fill: #016ca7;
}
.callout p+p {
  margin-top: 1em;
}

.callout a {
  color: #272eb5;
  font-weight: bold;
}

#gsk-logo {
  padding-top: 10px;
}
</style>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-3.3.4.min.js" integrity="sha384-5QIrjQuyo4I/x6DK/Sau33lcA3hT2TCZGr9vbk+2ebd7Da6FnR1amdM+9B5xOrSf" crossorigin="anonymous"></script>
<script src="https://cdn.bokeh.org/bokeh/release/bokeh-gl-3.3.4.min.js" integrity="sha384-tXTWPp/bAKa+K9RPuXh7DNvye0Mv+P+6y4rAMVy+pWapsnXg9UG7g20WZ0N4i28A" crossorigin="anonymous"></script>





<div class="main">
    <div id="gsk-rag" class="dark:text-white dark:bg-zinc-800 rounded border border-gray-500">
        <div class="header border-b border-b-gray-500">
            
                <svg xmlns="http://www.w3.org/2000/svg" width="60" height="30" viewBox="0 0 30 15" fill="none" id="gsk-logo">
                    <path fill="#fff" fill-rule="evenodd"
                        d="M22.504 1.549a4.196 4.196 0 0 1 2.573-.887v.002a3.783 3.783 0 0 1 2.706 1.086 3.783 3.783 0 0 1 1.126 2.69 3.771 3.771 0 0 1-1.126 2.69 3.77 3.77 0 0 1-2.706 1.085l-4.794.011-2.533 3.467L8.203 15l2.881-3.335a9.829 9.829 0 0 1-4.663-1.68H3.185L0 7.163h3.934C4.263 3.165 8.187 0 12.96 0c2.24 0 4.489.696 6.175 1.909a7.423 7.423 0 0 1 1.882 1.919 4.194 4.194 0 0 1 1.487-2.28ZM7.05 3.249l3.91 3.915h1.505L7.89 2.584a7.773 7.773 0 0 0-.84.665Zm4.079-2.008 5.923 5.923h1.503l-6.086-6.087c-.45.023-.898.078-1.34.164ZM4.574 8.226h-1.77l.784.693h1.584a8.454 8.454 0 0 1-.598-.693Zm9.479 0H5.984c1.469 1.477 3.656 2.377 5.977 2.422l2.092-2.422Zm-2.458 4.472 5.492-1.902 1.878-2.569h-3.508l-3.862 4.47Zm10.361-5.552h3.265a2.714 2.714 0 0 0 1.747-4.648 2.711 2.711 0 0 0-1.888-.773 3.127 3.127 0 0 0-3.123 3.124v2.297Zm3.659-3.73a.677.677 0 1 1-.134 1.348.677.677 0 0 1 .134-1.348Z"
                        clip-rule="evenodd" />
                </svg>
            <h1>RAG Evaluation Toolkit</h1>
        </div>
        
        <div class="section-container">
            <div class="components-container">
                
                <div class="component-card">
                    <div class="component-title">GENERATOR</div>
                    <div class="component-value tooltip  text-red ">
                        20.0%
                            <span class="tooltiptext" id="fade">The Generator is the LLM inside the RAG to generate the answers.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=20.0 class=" progress-red ">20.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">RETRIEVER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Retriever fetches relevant documents from the knowledge base according to a user query.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">REWRITER</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Rewriter modifies the user query to match a predefined format or to include the context from the chat history.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">ROUTING</div>
                    <div class="component-value tooltip  text-green ">
                        100.0%
                            <span class="tooltiptext" id="fade">The Router filters the query of the user based on his intentions (intentions detection).</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=100.0 class=" progress-green ">100.0%</progress>
                    </div>
                </div>
                
                <div class="component-card">
                    <div class="component-title">KNOWLEDGE_BASE</div>
                    <div class="component-value tooltip  text-orange ">
                        50.0%
                            <span class="tooltiptext" id="fade">The knowledge base is the set of documents given to the RAG to generate the answers. Its scores is computed differently from the other components: it is the difference between the maximum and minimum correctness score across all the topics of the knowledge base.</span>
                    </div>
                    <div class="component-bar">
                        <progress max="100" value=50.0 class=" progress-orange ">50.0%</progress>
                    </div>
                </div>
                
                <div class="overall-card">
                    <div class="overall-title">Overall Correctness Score</div>
                    <div class="overall-value">20%</div>
                </div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">RECOMMENDATION</div>
                <span class="section-content">Focus on improving the performance of the RAG system on complex questions, as it has the lowest score. Consider fine-tuning the Generator for better handling of complex question paraphrasing.</span>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">CORRECTNESS BY TOPIC</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"b949e1f3-69eb-4f40-aa56-1ab404cf5774":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Figure","id":"p1925","attributes":{"height":350,"width_policy":"max","x_range":{"type":"object","name":"DataRange1d","id":"p1927","attributes":{"start":0}},"y_range":{"type":"object","name":"FactorRange","id":"p1934","attributes":{"factors":["ACE Inhibitor Side Effects","Candesartan Cilexetil","NUCYNTA\\u2122 Medication","Others","Pharmaceuticals","Povidone Iodine Solution","Tizanidine Hydrochloride"]}},"x_scale":{"type":"object","name":"LinearScale","id":"p1935"},"y_scale":{"type":"object","name":"CategoricalScale","id":"p1936"},"title":{"type":"object","name":"Title","id":"p1932","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1954","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1922","attributes":{"selected":{"type":"object","name":"Selection","id":"p1923","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1924"},"data":{"type":"map","entries":[["correctness",{"type":"ndarray","array":{"type":"bytes","data":"JEmSJEmSPEAAAAAAAAAAAKqqqqqqqjBAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAElAAAAAAAAAOUA="},"shape":[7],"dtype":"float64","order":"little"}],["metadata_values",["ACE Inhibitor Side Effects","Candesartan Cilexetil","NUCYNTA\\u2122 Medication","Others","Pharmaceuticals","Povidone Iodine Solution","Tizanidine Hydrochloride"]],["colors",["#e3f399","#a50026","#fdbe6e","#a50026","#a50026","#006837","#fefebd"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1955","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1956"}}},"glyph":{"type":"object","name":"HBar","id":"p1951","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"fill_color":{"type":"value","value":"#14191B"}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1952","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1953","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"#1f77b4"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"#14191B"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1963","attributes":{"data_source":{"id":"p1922"},"view":{"type":"object","name":"CDSView","id":"p1964","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1965"}}},"glyph":{"type":"object","name":"HBar","id":"p1960","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"HBar","id":"p1961","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.1},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"HBar","id":"p1962","attributes":{"y":{"type":"field","field":"metadata_values"},"height":{"type":"value","value":0.85},"right":{"type":"field","field":"correctness"},"line_color":{"type":"value","value":"white"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"value","value":"#78BBFA"},"fill_alpha":{"type":"value","value":0.2},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1973","attributes":{"visible":false,"data_source":{"type":"object","name":"ColumnDataSource","id":"p1967","attributes":{"selected":{"type":"object","name":"Selection","id":"p1968","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1969"},"data":{"type":"map","entries":[["x",[0]],["y",[0]]]}}},"view":{"type":"object","name":"CDSView","id":"p1974","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1975"}}},"glyph":{"type":"object","name":"Line","id":"p1970","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_width":2,"line_dash":[6]}},"nonselection_glyph":{"type":"object","name":"Line","id":"p1971","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.1,"line_width":2,"line_dash":[6]}},"muted_glyph":{"type":"object","name":"Line","id":"p1972","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"line_color":"#EA3829","line_alpha":0.2,"line_width":2,"line_dash":[6]}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1933","attributes":{"tools":[{"type":"object","name":"HoverTool","id":"p1947","attributes":{"renderers":"auto","tooltips":[["topic","@metadata_values"],["Correctness","@correctness{0.00}"]]}}]}},"toolbar_location":null,"left":[{"type":"object","name":"CategoricalAxis","id":"p1942","attributes":{"ticker":{"type":"object","name":"CategoricalTicker","id":"p1943"},"formatter":{"type":"object","name":"CategoricalTickFormatter","id":"p1944"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1945"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1937","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1938","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1939"},"axis_label":"Correctness (%)","axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1940"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1941","attributes":{"axis":{"id":"p1937"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1946","attributes":{"dimension":1,"axis":{"id":"p1942"},"grid_line_color":"#E0E0E0","grid_line_alpha":0.25}},{"type":"object","name":"Span","id":"p1966","attributes":{"location":20.0,"dimension":"height","line_color":"#EA3829","line_width":2,"line_dash":[6]}},{"type":"object","name":"Legend","id":"p1976","attributes":{"border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1977","attributes":{"label":{"type":"value","value":"Correctness on the entire Testset"},"renderers":[{"id":"p1973"}]}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}]}}';
        const render_items = [{"docid":"b949e1f3-69eb-4f40-aa56-1ab404cf5774","roots":{"p1925":"ef356b54-8e81-4801-9ba7-5d65fed89585"},"root_ids":["p1925"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="ef356b54-8e81-4801-9ba7-5d65fed89585" data-root-id="p1925" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">
                <div class="section-title">KNOWLEDGE BASE OVERVIEW</div>
                    <script type="text/javascript">
        (function() {
  const fn = function() {
    Bokeh.safely(function() {
      (function(root) {
        function embed_document(root) {
        const docs_json = '{"c19a263b-e8a0-4fe8-9504-ab9ec59e8ea7":{"version":"3.4.3","title":"Bokeh Application","roots":[{"type":"object","name":"Tabs","id":"p1856","attributes":{"sizing_mode":"stretch_width","tabs":[{"type":"object","name":"TabPanel","id":"p1786","attributes":{"title":"Topic exploration","child":{"type":"object","name":"Figure","id":"p1736","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1745","attributes":{"start":2.6081478595733643,"end":17.234113693237305}},"y_range":{"type":"object","name":"Range1d","id":"p1746","attributes":{"start":13.671540260314941,"end":21.66947841644287}},"x_scale":{"type":"object","name":"LinearScale","id":"p1747"},"y_scale":{"type":"object","name":"LinearScale","id":"p1748"},"title":{"type":"object","name":"Title","id":"p1743","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1776","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1733","attributes":{"selected":{"type":"object","name":"Selection","id":"p1734","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1735"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["topic",["Pharmaceutical Products","Pharmaceutical Products","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Medication Information","Others","Others","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","ACE Inhibitors","Others","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Medication Information","Others","Medication Information","Medication Information","Pharmaceutical Products","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Candesartan Cilexetil","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Tizanidine Overdose","Pharmaceutical Products","Others","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Others","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products","Pharmaceutical Products"]],["id",[0,1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118]],["content",["ADEA GARGLE- citric acid, sodium hydrogen carbonate, xylitol tablet, chewable \\n \\nK2resource co., ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nCITRIC ACID, SODIUM HYDROGEN CARBONATE, XYLITOL\\nFor oral care: Tooth whitening, removing bad breath, preventing tooth decay, preventing gingivitis and\\ntartar formation, plaque removal, oral cleansing\\nKeep...","K2resource co., ltd.\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:72191-0100\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nSODIUM BICARBONATE\\n (UNII: 8MDF5V39QO) \\n(SODIUM CATION -\\nUNII:LYR4M0NH37)\\nSODIUM\\nBICARBONATE\\n36.2 g  in 100 mg\\nXYLITOL\\n (UNII: VCQ006KQ1E) \\n(XYLITOL - UNII:VCQ006KQ1E)\\nXYLITOL\\n5 g  in 100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMENTHOL\\n (UNII: L7T10EIP3A)\\n \\nProduct Characteristics\\nCo...","NUCYNTA - tapentadol hydrochloride tablet, film coated \\n \\nStat Rx USA\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use NUCYNTA\\u2122 safely and effectively. See full\\nprescribing information for NUCYNTA\\u2122.\\n \\nNUCYNTA\\u2122 (tapentadol) immediate-release oral tablets    C-II\\nInitial U.S. Approval: 2008\\nRECENT MAJOR CHANGES\\nWarnings and Precautions (\\n5.4\\n)\\nJune 2009\\nINDICATIONS AND USAGE\\nNUCYNTA\\u2122 is an opioid analgesic indicated for the relief o...","USE IN SPECIFIC POPULATIONS\\nLabor and delivery: \\nshould not use during and immediately prior to labor and delivery. Monitor neonates, whose\\nmothers have been taking NUCYNTA\\u2122, for respiratory depression. (\\n8.2\\n)\\nNursing mothers: should not breast-feed. (\\n8.3\\n)\\nPediatric use: safety and effectiveness not established in patients less than 18 years of age. (\\n8.4\\n)\\nRenal or hepatic impairment: not recommended in patients with severe renal or hepatic impairment. Use with caution in\\npatients with moder...","8.7 Hepatic Impairment\\n9 DRUG ABUSE AND DEPENDENCE\\n9.1 Controlled Substance\\n9.2 Abuse\\n9.3 Dependence\\n10 OVERDOSAGE\\n10.1 Human Experience\\n10.2 Management of Overdose\\n11 DESCRIPTION\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\n12.2 Pharmacodynamics\\n12.3 Pharmacokinetics\\n13 NON-CLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n13.2 Animal Toxicology and/or Pharmacology\\n14 CLINICAL STUDIES\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\n14.2 End-Stage Degenerative Joint Disea...","Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not\\nbeen studied and are not recommended.\\nNUCYNTA\\u2122 may be given with or without food \\n[see \\nClinical Pharmacology (12.3)\\n].\\n2.1 Renal Impairment\\nNo dosage adjustment is recommended in patients with mild or moderate renal impairment \\n[see \\nClinical\\nPharmacology (12.3)\\n]\\n.\\nNUCYNTA\\u2122 has not been studied in patients with severe renal impairment. The use in this population\\nis not recommended.\\n2.2 Hepatic Im...","which may result in adverse cardiovascular events \\n[see \\nDrug Interactions (7.4)\\n]\\n.\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Respiratory Depression\\nRespiratory depression is the primary risk of mu-opioid agonists. Respiratory depression occurs more\\nfrequently in elderly or debilitated patients and in those suffering from conditions accompanied by\\nhypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may\\nsignificantly decrease pulmonary ventilation.\\nNUCYNTA\\u2122 should be ...","5.5 Driving and Operating Machinery\\nPatients should be cautioned that NUCYNTA\\u2122 may impair the mental and/or physical abilities required\\nfor the performance of potentially hazardous tasks such as driving a car or operating machinery. This is\\nto be expected especially at the beginning of treatment, at any change of dosage as well as in\\ncombination with alcohol or tranquilizers\\n [see \\nDrug Interactions (7.3)\\n]\\n.\\n5.6 Interactions with Alcohol and Drugs of Abuse\\nDue to its mu-opioid agonist activity,...","Because clinical studies are conducted under widely varying conditions, adverse event rates observed\\nin the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another\\ndrug and may not reflect the rates observed in clinical practice. A treatment-emergent adverse event\\nrefers to any untoward medical event associated with the use of the drug in humans, whether or not\\nconsidered drug-related.\\nBased on data from nine Phase 2/3 studies that administered multiple...","*\\nInfections and infestations\\n  Nasopharyngitis\\n1\\n&lt;1\\n  Upper respiratory tract infection\\n1\\n&lt;1\\n  Urinary tract infection\\n1\\n&lt;1\\nMetabolism and nutrition disorders\\n  Decreased appetite\\n2\\n0\\nMusculoskeletal and connective tissue\\ndisorders\\n  Arthralgia\\n1\\n&lt;1\\nNervous system disorders\\n  Dizziness\\n24\\n8\\n  Somnolence\\n15\\n3\\n  Tremor\\n1\\n&lt;1\\n  Lethargy\\n1\\n&lt;1\\nPsychiatric disorders\\n  Insomnia\\n2\\n&lt;1\\n  Confusional state\\n1\\n0\\n  Abnormal dreams\\n1\\n&lt;1\\n  Anxiety\\n1\\n&lt;1\\nSkin and subcutaneous tissue disorders\\n  Pruritus\\n5\\n1\\n  Hyp...","Psychiatric disorders:\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\nabnormal\\nRenal and urinary disorders:\\n urinary hesitation, pollakiuria\\nRespiratory, thoracic and mediastinal disorders: \\noxygen saturation decreased, cough, dyspnea,\\nrespiratory depression\\nSkin and subcutaneous tissue disorders: \\nurticaria\\nVascular disorders:\\n blood pressure decreased\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\nNUCYNTA\\u2122,...","Pregnancy Category C.\\nTapentadol HCl was evaluated for teratogenic effects in pregnant rats and rabbits following intravenous\\nand subcutaneous exposure during the period of embryofetal organogenesis. When tapentadol was\\nadministered twice daily by the subcutaneous route in rats at dose levels of 10, 20, or 40 mg/kg/day\\n[producing up to 1 times the plasma exposure at the maximum recommended human dose (MRHD) of\\n700 mg/day based on an area under the time-curve (AUC) comparison], no teratogenic eff...","as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\npatients with the lower range of recommended doses \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n8.6 Renal Impairment\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\u2122 has not been\\nestablished. NUCYNTA\\u2122 is not recommended in this population \\n[see \\nDosage and Adminis...","Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and\\nproper dispensing and storage are appropriate measures that help to limit abuse of drugs with mu-opioid\\nagonist properties.\\nInfants born to mothers physically dependent on opioids will also be physically dependent and may\\nexhibit respiratory difficulties and withdrawal symptoms \\n[see \\nWarnings and Precautions (5.1)\\n]\\n. Use of\\nNUCYNTA\\u2122 in this population has not been characterized. As NUCYNTA\\u2122 h...","intoxication with exceptionally large quantities. Before attempting gastrointestinal decontamination, care\\nshould be taken to secure the airway.\\n11 DESCRIPTION\\nNUCYNTA\\u2122 (tapentadol) Tablets are immediate-release film-coated tablets for oral administration.\\nThe chemical name is 3-[(1\\nR\\n,2\\nR\\n)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol\\nmonohydrochloride. The structural formula is:\\nThe molecular weight of tapentadol HCl is 257.80, and the molecular formula is C\\nH\\nNO\\u00b7HCl. The\\nn-octanol:water pa...","extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\naround 1.25 hours after dosing.\\nDose-proportional increases in the C\\n and AUC values of tapentadol have been observed over the 50\\nto 150 mg dose range.\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\nglucuronide, which are primarily determined by the do...","Pharmacokinetic Drug Interactions\\nTapentadol is mainly metabolized by Phase 2 glucuronidation, a high capacity/low affinity system,\\ntherefore, clinically relevant interactions caused by Phase 2 metabolism are unlikely to occur. Naproxen\\nand probenecid increased the AUC of tapentadol by 17% and 57%, respectively. These changes are not\\nconsidered clinically relevant and no change in dose is required.\\nNo changes in the pharmacokinetic parameters of tapentadol were observed when acetaminophen and\\nac...","14 CLINICAL STUDIES\\nThe efficacy and safety of NUCYNTA\\u2122 in the treatment of moderate to severe acute pain has been\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\u2122...","50% or greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus\\nplacebo.\\n14.2 End-Stage Degenerative Joint Disease\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\nevaluated the efficacy and safety of 50 mg and 75 mg NUCYNTA\\u2122 given every 4 to 6 hours during\\nwaking hours for 10 days in patients aged 18 to 80 years, experiencing moderate to severe pain from\\nend stage degenerative joint disease of the hip or knee, defined...","The proportions of patients who showed reduction in pain intensity at 5 days of 30% or greater, or 50%\\nor greater were significantly higher in patients treated with NUCYNTA\\u2122 at each dose versus placebo.\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\nNUCYNTA\\u2122 Tablets are available in the following strengths and packages. All tablets are round and\\nbiconvex-shaped.\\n50 mg tablets are yellow and debossed with \\"O-M\\" on one side and \\"50\\" on the other side, and are\\navailable in bottles of 100 (NDC 50458-820-04) a...","Patients should be advised not to breast-feed an infant during treatment with NUCYNTA\\u2122 \\n[see \\nUse in\\nSpecific Populations (8.3)\\n]\\n.\\n17.6 Monoamine Oxidase Inhibitors\\nPatients should be informed not to take NUCYNTA\\u2122 while using any drugs that inhibit monoamine\\noxidase. Patients should not start any new medications while taking NUCYNTA\\u2122 until they are assured\\nby their healthcare provider that the new medication is not a monoamine oxidase inhibitor.\\n17.7 Seizures\\nPatients should be informed that NU...","you get a new prescription. There may be new information. This Medication Guide does not take\\nthe place of talking to your doctor about your medical condition or your treatment. Talk to your\\ndoctor if you have any questions.\\nWhat is the most important information I should know about NUCYNTA\\u2122?\\nNUCYNTA\\u2122 is a tablet that contains tapentadol, a strong medicine that is a pain medicine.\\nUse NUCYNTA\\u2122 exactly how your doctor tells you to. Do not use NUCYNTA\\u2122 if it has not been\\nprescribed for you.\\nYou sh...","Do not change the dose of NUCYNTA\\u2122 unless your doctor tells you to. \\nYour doctor may\\nchange your dose after seeing how the medicine affects you. Do not use NUCYNTA\\u2122 more often\\nthan prescribed. Call your doctor if your pain is not well controlled while taking NUCYNTA\\u2122.\\nFollow your doctor&#x27;s instructions about how to slowly stop taking NUCYNTA\\u2122 to help lessen\\nwithdrawal symptoms.\\nNUCYNTA\\u2122 can be taken with or without food.\\nWhat should I avoid while taking NUCYNTA\\u2122?\\nDo not drive, operate machinery, ...","Store NUCYNTA\\u2122 at 59\\u00baF to 86\\u00baF (15\\u00baC to 30\\u00baC). Keep NUCYNTA\\u2122 tablets dry.\\nDispose of NUCYNTA\\u2122 tablets you no longer need.\\nKeep NUCYNTA\\u2122 in a safe place out of the reach of children.\\nGeneral information about NUCYNTA\\u2122\\nMedicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not\\nuse NUCYNTA\\u2122 for a condition for which it was not prescribed. \\nDo not give NUCYNTA\\u2122 to other\\npeople, even if they have the same symptoms you have. Sharing NUCYNTA\\u2122 could be harmful\\n...","NUCYNTA 100MG PACKAGE LABEL\\n       \\n   \\n   \\n   \\n   \\n   \\n   \\nNUCYNTA  \\ntapentadol hydrochloride tablet, film coated\\nProduct Information\\nProduct Type\\nHUMAN\\nPRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:16590-\\n863(NDC:50458-820)\\nRoute of Administration\\nORAL\\nDEA Schedule\\nCII","Active Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n50 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII: 15FIX9V2JP)\\n...","Stat Rx USA\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII:...","GRX DYNE - povidone iodine solution \\n \\nGeritrex Corp.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nGRx Dyne Solution\\nDrug Facts\\nActive Ingredient:                      Purpose\\nPovidone Iodine USP, 10% w/v  Antiseptic\\n(equivalent to 1% titratable Iodine)\\nUses\\nFirst aid antiseptic to help the risk of infection in \\nminor cuts, scra...","Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\nkeep out of reach of children. If swallowed get medical help \\nor contact a Poison Control Center right away.\\nEnter section text here\\nGRX DYNE  \\npovidone iodine solution\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:54162-269\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85...","Geritrex Corp.\\nCITRIC ACID MONOHYDRATE\\n (UNII: 2968PHW8QP)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nWATER\\n (UNII: 059QF0KO0R)\\n \\nSODIUM HYDROXIDE\\n (UNII: 55X04QC32I)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:54162-269-16\\n472 mL in 1 BOTTLE, PLASTIC\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOTC monograph not final\\npart333A\\n05/16/2012\\nLabeler - \\n...","LISINOPRIL AND HYDROCHLOROTHIAZIDE- lisinopril and hydrochlorothiazide\\ntablets tablet \\n \\nCipla USA Inc.\\n----------\\nLisinopril and Hydrochlorothiazide Tablets, USP\\nRx Only\\nWARNING: FETAL TOXICITY\\nSee full prescribing information for complete boxed warning.\\nWhen pregnancy is detected, discontinue lisinopril and\\nhydrochlorothiazide tablets as soon as possible.\\nDrugs that act directly on the renin-angiotensin system can cause\\ninjury and death to the developing fetus. See \\nWarnings: Fetal Toxicity\\n.\\n...","Hydrochlorothiazide, USP is a white, or practically white, crystalline powder with a\\nmolecular weight of 297.72, which is slightly soluble in water, but freely soluble in sodium\\nhydroxide solution.\\nLisinopril and hydrochlorothiazide tablets, USP are available for oral use in three tablet\\ncombinations of lisinopril with hydrochlorothiazide: lisinopril and hydrochlorothiazide\\ntablets 10 mg/12.5 mg, containing 10 mg lisinopril and 12.5 mg hydrochlorothiazide,\\nlisinopril and hydrochlorothiazide tabl...","Concomitant administration of lisinopril and hydrochlorothiazide has little or no effect on\\nthe bioavailability of either drug. The combination tablet is bioequivalent to concomitant\\nadministration of the separate entities.\\nLisinopril\\nMechanism of Action\\n \\nLisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals.\\nACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the\\nvasoconstrictor substance, angiotensin II. Angiotensin II also stimulate...","state is prolonged. Older patients, on average, have (approximately doubled) higher\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\npatients (see \\nDOSAGE AND ADMINISTRATION\\n). In a multiple dose pharmacokinetic study\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\nhe...","accompanied by some loss of potassium and bicarbonate.\\nAfter oral use diuresis begins within two hours, peaks in about four hours and lasts\\nabout 6 to 12 hours.\\nHydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney. When\\nplasma levels have been followed for at least 24 hours, the plasma half-life has been\\nobserved to vary between 5.6 and 14.8 hours. At least 61 percent of the oral dose is\\neliminated unchanged within 24 hours. Hydrochlorothiazide crosses the placental but...","the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused\\nagranulocytosis, particularly in patients with renal impairment or collagen vascular\\ndisease, and that available data are insufficient to show that lisinopril does not have a\\nsimilar risk (See \\nWARNINGS\\n).\\nIn considering the use of lisinopril and hydrochlorothiazide tablets, USP it should be\\nnoted that ACE inhibitors have been associated with a higher rate of angioedema in black\\nthan in nonblack patients (see \\nWARNIN...","Patients receiving coadministration of ACE inhibitor and mTOR (mammalian target of\\nrapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy or a neprilysin\\ninhibitor may be at increased risk for angioedema (see \\nPRECAUTIONS\\n).\\nIntestinal Angioedema:\\n Intestinal angioedema has been reported in patients treated\\nwith ACE inhibitors. These patients presented with abdominal pain (with or without\\nnausea or vomiting); in some cases there was no prior history of facial angioedema and\\nC-1...","myocardial infarction or cerebrovascular accident.\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\nresponse is not a contraindication to further doses which usually can be given without\\ndifficulty once the blood pressure has increased after volume expansion.\\nLeukopenia/Neutropenia/Agranulocytosis:\\n Another angiotensin-converting enzyme\\ninhibitor, captopril, has been shown to ca...","rabbits. On a mg/kg basis, the doses used were up to 625 times (in mice), 188 times (in\\nrats), and 0.6 times (in rabbits) the maximum recommended human dose.\\nLisinopril and Hydrochlorothiazide\\nTeratogenicity studies were conducted in mice and rats with up to 90 mg/kg/day of\\nlisinopril (56 times the maximum recommended human dose) in combination with 10\\nmg/kg/day of hydrochlorothiazide (2.5 times the maximum recommended human dose).\\nMaternal or fetotoxic effects were not seen in mice with the com...","Lithium generally should not be given with thiazides (See PRECAUTIONS, Drug\\nInteractions, Lisinopril and Hydrochlorothiazide).\\nPRECAUTIONS\\nGeneral\\nLisinopril\\n \\nAortic Stenosis/Hypertrophic Cardiomyopathy:\\n As with all vasodilators, lisinopril\\nshould be given with caution to patients with obstruction in the outflow tract of the left\\nventricle.\\nImpaired Renal Function:\\n As a consequence of inhibiting the renin-angiotensin-\\naldosterone system, changes in renal function may be anticipated in suscept...","be due to this mechanism, it can be corrected by volume expansion.\\nHydrochlorothiazide\\n \\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\nshould be performed at appropriate intervals.\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\nSerum and urine electrolyte determinations are particularly important when the patient is\\nvomiting exc...","therapy.\\nInformation for Patients\\nAngioedema:\\n Angioedema, including laryngeal edema may occur at any time during\\ntreatment with angiotensin-converting enzyme inhibitors, including lisinopril and\\nhydrochlorothiazide. Patients should be so advised and told to report immediately any\\nsigns or symptoms suggesting angioedema (swelling of face, extremities, eyes, lips,\\ntongue, difficulty in swallowing or breathing) and to take no more drug until they have\\nconsulted with the prescribing physician.\\nSymp...","DOSAGE AND ADMINISTRATION\\n)\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2\\nInhibitors (COX-2 Inhibitors):\\n \\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or\\nwith compromised renal function, co-administration of NSAIDs, including selective COX-2\\ninhibitors, with ACE inhibitors, including lisinopril, may result in deterioration of renal\\nfunction, including possible acute renal failure. These effects are usually reversible.\\nMonitor ...","mTOR (mammalian target of rapamycin) inhibitors\\n \\nPatients receiving coadministration of ACE inhibitor and mTOR inhibitor (e.g.,\\ntemsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema.\\n(see \\nWARNINGS\\n)\\nNeprilysin Inhibitors Patients taking concomitant neprilysin inhibitors may be at increased\\nrisk for angioedema. (see \\nWARNINGS\\n)\\nHydrochlorothiazide\\nWhen administered concurrently the following drugs may interact with thiazide diuretics.\\nAlcohol, barbiturates, or nar...","in vitro\\n alkaline elution rat hepatocyte assay. In addition, it did not produce increases in\\nchromosomal aberrations in an \\nin vitro\\n test in Chinese hamster ovary cells or in an \\nin\\nvivo\\n study in mouse bone marrow.\\nLisinopril\\n \\nThere was no evidence of a tumorigenic effect when lisinopril was administered for 105\\nweeks to male and female rats at doses up to 90 mg/kg/day (about 56 or 9 times* the\\nmaximum daily human dose, based on body weight and body surface area,\\nrespectively). There was no ...","Nursing Mothers\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\nrats contains radioactivity following administration of \\nC lisinopril. In another study,\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\nwhether to discontinue nursing and/or disco...","adverse effects was required in 4.4% of patients principally because of dizziness, cough,\\nfatigue and muscle cramps.\\nAdverse experiences occurring in greater than one percent of patients treated with\\nlisinopril plus hydrochlorothiazide in controlled clinical trials are shown below.\\n                                                                         Percent of Patients in\\nControlled Studies\\n   Lisinopril and\\nHydrochlorothiazide\\n   (n=930)\\n   Incidence\\n(discontinuation)\\n   Placebo\\n   (n=207)\\n...","In rare cases, intestinal angioedema has been reported in post marketing experience.\\nHypotension:\\n In clinical trials, adverse effects relating to hypotension occurred as\\nfollows: hypotension (1.4%), orthostatic hypotension (0.5%), other orthostatic effects\\n(3.2%). In addition syncope occurred in 0.8% of patients (See \\nWARNINGS\\n).\\nCough:\\n See \\nPRECAUTIONS - Cough\\n.\\nClinical Laboratory Test Findings Serum Electrolytes:\\n (See \\nPRECAUTIONS\\n).\\nCreatinine, Blood Urea Nitrogen:\\n Minor reversible incre...","hallucinations; \\nRespiratory:\\n Malignant lung neoplasms, hemoptysis, pulmonary edema,\\npulmonary infiltrates, bronchospasm, asthma, pleural effusion, pneumonia, eosinophilic\\npneumonitis, wheezing, orthopnea, painful respiration, epistaxis, laryngitis, sinusitis,\\npharyngitis, rhinitis, rhinorrhea, chest sound abnormalities; \\nSkin:\\n Urticaria, alopecia,\\nherpes zoster, photosensitivity, skin lesions, skin infections, pemphigus, erythema,\\npsoriasis, rare cases of other severe skin reactions, includin...","Lisinopril\\n \\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\nnormal saline solution.\\nLisinopril can be removed by hemodialysis (see \\nWARNINGS, Anaphylactoid Reaction\\nDuring Membrane Exposure\\n).\\nHydrochlorothiazide\\n \\nOral administration of a single oral dose of 10 g/kg to mice and rats w...","possible, be discontinued for two to three days before beginning therapy with lisinopril\\nto reduce the likelihood of hypotension (See \\nWARNINGS\\n). If the patient\\u2019s blood pressure\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\nfor at least an additional hour (See \\nWARNINGS\\n and \\nPRECAUTIONS\\n...","Protect from excessive light and humidity.\\n*AN69 is a registered trademark of Hospal Ltd.\\nManufactured by:\\nInvaGen Pharmaceuticals, Inc.\\n(a subsidiary of Cipla Ltd.)\\nHauppauge, NY 11788\\nManufactured for:\\nCipla USA, Inc.\\n10 Independence Boulevard, Suite 300\\nWarren, NJ 07059\\nRevised: 10/2021\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\u2013 10 mg/12.5 mg\\nNDC 69097-968-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n10 mg/12.5 mg\\n100 Tablets\\nCipla\\nNDC 69097-969-07             ...","Cipla\\nNDC 69097-971-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n20 mg/25 mg\\n100 Tablets\\nCipla\\nLISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-968\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n10 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\n (UNII: L11K75P92J)\\n \\nMAN...","lisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-969\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS D...","LISINOPRIL AND HYDROCHLOROTHIAZIDE  \\nlisinopril and hydrochlorothiazide tablets tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-971\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n20 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n25 mg\\nInactive Ingredients\\nI...","Cipla USA Inc.\\nLabeler - \\nCipla USA Inc. \\n(078719707)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen\\nPharmaceuticals, Inc\\n165104469\\nanalysis(69097-968, 69097-969, 69097-971) , manufacture(69097-968,\\n69097-969, 69097-971)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nInvaGen Pharmaceuticals, Inc\\n080334903\\npack(69097-968, 69097-969, 69097-971)\\n \\nRevised: 11/2021","ALLERGY MULTI SYMPTOM- acetaminophen, chlorpheniramine maleate, and\\nphenylephrine hydrochloride tablet, coated \\n \\nMARC GLASSMAN, INC.\\n----------\\n1128B-MAR-2022-1005\\nDrug Facts\\nActive ingredients \\n(in each caplet)\\nPurpose\\nAcetaminophen 325 mg\\nPain reliever\\nChlorpheniramine maleate\\n2 mg\\nAntihistamine\\nPhenylephrine HCl 5 mg\\nNasal decongestant\\nUses\\ntemporarily relieves these symptoms of hay fever or other upper respiratory\\nallergies:\\nheadache\\nsinus congestion and pressure\\nnasal congestion\\nrunny nose...","If a skin reaction occurs, stop use and seek medical help right away.\\nDo not use\\nwith any other drug containing acetaminophen (prescription or nonprescription). If\\nyou are not sure whether a drug contains acetaminophen, ask a doctor or\\npharmacist.\\nif you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain\\ndrugs for depression, psychiatric or emotional conditions, or Parkinson&#x27;s disease), or\\nfor 2 weeks after stopping the MAOI drug. If you do not know if your prescription\\ndr...","800-222-1222). Quick medical attention is critical for adults as well as for children even if\\nyou do not notice any signs or symptoms.\\nDirections\\ndo not take more than directed (see \\noverdose warning\\n)\\nadults and\\nchildren 12\\nyears and over\\ntake 2 caplets every 4 hours\\nswallow whole; do not crush,\\nchew, or dissolve\\ndo not take more than 10 caplets\\nin 24 hours\\nchildren under \\n12 years\\nask a doctor\\nOther information\\nstore between 20\\u00b0-25\\u00b0C (68\\u00b0-77\\u00b0F) in a dry place\\nretain carton for complete product...","ALLERGY MULTI SYMPTOM  \\nacetaminophen, chlorpheniramine maleate, and phenylephrine hydrochloride tablet, coated\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:68998-228\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCHLORPHENIRAMINE MALEATE\\n (UNII: V1Q0O9OJ9Z) \\n(CHLORPHENIRAMINE -\\nUNII:3U6IO1965U)\\nCHLORPHENIRAMINE\\nMALEATE\\n2 mg\\nPHENYLEPHRINE HYDROCHLORIDE\\n (UNII: 04JA59TNSJ) \\n(PHENYLEPHRINE -\\nUNII:1WS297W6MV)\\nPHENYLE...","MARC GLASSMAN, INC.\\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nFERRIC OXIDE YELLOW\\n (UNII: EX438O2MRT)\\n \\nMAGNESIUM STEARATE\\n (UNII: 70097M6I30)\\n \\nCROSPOVIDONE\\n (UNII: 2S7830E561)\\n \\nCELLULOSE, MICROCRYSTALLINE\\n (UNII: OP1R32D61U)\\n \\nPOLYETHYLENE GLYCOL, UNSPECIFIED\\n (UNII: 3WJQ0SDW1A)\\n \\nPOLYVINYL ALCOHOL, UNSPECIFIED\\n (UNII: 532B59J990)\\n \\nPOVIDONE, UNSPECIFIED\\n (UNII: FZ989GH94E)\\n \\nSTARCH, CORN\\n (UNII: O8232NY3SJ)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nSTEA...","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE- candesartan cilexetil and\\nhydrochlorothiazide tablet \\n \\nANI Pharmaceuticals, Inc.\\n----------\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\nWARNING: \\nFETAL TOXICITY\\n\\u2022\\n\\u2022\\nDESCRIPTION\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP combine an angiotensin II receptor (type\\nAT\\n) antagonist and a diuretic, hydrochlorothiazide.\\nCandesartan cilexetil, a nonpeptide, is chemically described as (\\u00b1)-1-Hydroxyethyl 2-ethoxy-1-[\\np\\n-(\\no\\n-\\n1\\nH\\n...","Hydrochlorothiazide is a white, or practically white, crystalline powder with a molecular weight of\\n297.72, which is slightly soluble in water, but freely soluble in sodium hydroxide solution.\\nCandesartan cilexetil and hydrochlorothiazide tablets are available for oral administration in three tablet\\nstrengths of candesartan cilexetil and hydrochlorothiazide.\\nCandesartan cilexetil and hydrochlorothiazide tablets contain 16 mg or 32 mg of candesartan cilexetil\\nand 12.5 mg or 25 mg of hydrochloroth...","The mechanism of the antihypertensive effect of thiazides is unknown.\\nPharmacokinetics\\nGeneral\\nCandesartan Cilexetil\\nCandesartan cilexetil is rapidly and completely bioactivated by ester hydrolysis during absorption from\\nthe gastrointestinal tract to candesartan, a selective AT\\nsubtype angiotensin II receptor antagonist.\\nCandesartan is mainly excreted unchanged in urine and feces (via bile). \\nIt undergoes minor hepatic\\nmetabolism by O-deethylation to an inactive metabolite. \\nThe elimination half...","Geriatric\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\u2265 65 years). \\nThe plasma\\nconcentration of candesartan was higher in the elderly (C\\n was approximately 50% higher, and AUC\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\nThe\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\nNo initia...","plasma concentration of aldosterone was observed when 32 mg of candesartan cilexetil was\\nadministered to hypertensive patients. \\nIn spite of the effect of candesartan cilexetil on aldosterone\\nsecretion, very little effect on serum potassium was observed.\\nIn multiple-dose studies with hypertensive patients, there were no clinically significant changes in\\nmetabolic function including serum levels of total cholesterol, triglycerides, glucose, or uric acid. \\nIn a\\n12-week study of 161 patients with n...","in myocardial infarction and cardiovascular mortality also have been seen regularly.\\nElevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk\\nincrease per mmHg is greater at higher blood pressures, so that even modest reductions of severe\\nhypertension can provide substantial benefit. \\nRelative risk reduction from blood pressure reduction is\\nsimilar across populations with varying absolute risk, so the absolute benefit is greater in patients who\\nare at h...","candesartan cilexetil was 1 mg/kg/day (a maternally toxic dose that is about half the MRHD\\n). \\nIn each of\\nthese studies, hydrochlorothiazide was tested at the same dose level (10 mg/kg/day, about 4, 8, and 15\\ntimes the MRHD\\n in mouse, rats, and rabbit, respectively). \\nThere was no evidence of harm to the rat or\\nmouse fetus or embryo in studies in which hydrochlorothiazide was administered alone to the pregnant\\nrat or mouse at doses of up to 1000 and 3000 mg/kg/day, respectively.\\nThiazides cross ...","considered if the intraocular pressure remains uncontrolled. \\nRisk factors for developing acute angle-\\nclosure glaucoma may include a history of sulfonamide or penicillin allergy.\\nHypersensitivity Reaction\\nHypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of\\nallergy or bronchial asthma, but are more likely in patients with such a history.\\nPRECAUTIONS\\nMetabolic Disturbances\\nHydrochlorothiazide may alter glucose tolerance and raise serum levels of ch...","Interactions common to both Candesartan Cilexetil and Hydrochlorothiazide\\nNon-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)\\nIn patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised\\nrenal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II\\nreceptor antagonists, including candesartan, may result in deterioration of renal function, including\\npossible ac...","Cytotoxic products \\u2013 Thiazides may reduce the renal excretion of cytotoxic medicinal products (e.g.\\ncyclophosphamide, methotrexate) and potentiate their myelosuppressive effects.\\nCyclosporine \\u2212 Concomitant treatment with cyclosporine may increase the risk of hyperuricemia and\\ngout-type complications.\\nCarcinogenesis, Mutagenesis, Impairment of Fertility\\nNo carcinogenicity studies have been conducted with the combination of candesartan cilexetil and\\nhydrochlorothiazide. \\nThere was no evidence of c...","Neonates with a history of in utero exposure to candesartan cilexetil and hydrochlorothiazide tablets:\\nIf oliguria or hypotension occurs, direct attention toward support of blood pressure and renal perfusion.\\nExchange transfusions or dialysis may be required as a means of reversing hypotension and/or\\nsubstituting for disordered renal function.\\nSafety and effectiveness in pediatric patients have not been established.\\nADVERSE REACTIONS\\nCandesartan Cilexetil and Hydrochlorothiazide\\nCandesartan cile...","melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\nfor white patients taking a cumulative dose of \\u226550,000 mg the risk increase was approximately 1\\nadditional SCC case for every 6,700 patients per year.\\nSkin:\\n \\nerythema multiforme including S...","Dose Titration by Clinical Effect: \\nA patient whose blood pressure is not controlled on 25 mg of\\nhydrochlorothiazide once daily can expect an incremental effect from candesartan cilexetil and\\nhydrochlorothiazide tablets 16 mg/12.5 mg. \\nA patient whose blood pressure is controlled on 25 mg of\\nhydrochlorothiazide but is experiencing decreases in serum potassium can expect the same or\\nincremental blood pressure effects from candesartan cilexetil and hydrochlorothiazide tablets 16\\nmg/12.5 mg and ser...","PRINCIPAL DISPLAY PANEL \\u2013 32 mg/12.5 mg\\nNDC 62559-661-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/12.5 mg\\nRx only\\n90 Tablets\\nPRINCIPAL DISPLAY PANEL \\u2013 32 mg/25 mg\\nNDC 62559-662-90\\nCandesartan Cilexetil and Hydrochlorothiazide Tablets USP\\n32 mg/25 mg\\nRx only\\n90 Tablets","CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:62559-660\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nCANDESARTAN CILEXETIL\\n (UNII: R85M2X0D68) \\n(CANDESARTAN - UNII:S8Q36MD2XX)\\nCANDESARTAN\\nCILEXETIL\\n16 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n1...","Flavor\\nImprint Code\\nACS\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-660-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type...","Packaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-661-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (So...","ANI Pharmaceuticals, Inc.\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-662-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nLabeler - \\nANI Pharmaceuticals, Inc. \\n(145588013)\\n \\nRevised: 5/2020","CERTUS PVP-1 PREP SWABSTICK - povidone-iodine swab \\n \\nCertus Medical, Inc.\\nDisclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they\\ncomply with applicable regulations and policies. FDA has not evaluated whether this product complies.\\n----------\\nCertus PVP-1 Prep Swabstick 210012 Drug Facts and Label\\nDrug Facts Box OTC Active Ingredient Section\\nPovidone Iodine USP 10%\\nequivalent to 1% titratable iodine\\nDrug Facts Box OTC Purpose Section\\nAntiseptic\\nDrug...","Drug Facts Box OTC General Precautions Section\\nstore at room temperature 15\\n - 30\\n C (59\\n - 86\\n F)\\nDrug Facts Box OTC Inactive Ingredient Section\\ndisodium phosphate, glycerin, hydroxyethylcellulose, nonoxynol-10, dimethicone, water\\nCertus PVP-1 Prep Swabstick \\n210012 pouch\\n210012.jpg  Certus PVP-1 Prep Swabstick  pouch  \\n0\\n0\\n0\\n0","CERTUS PVP-1 PREP SWABSTICK  \\npovidone-iodine swab\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:75990-4019\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85H0HZU99M) \\n(POVIDONE-IODINE - UNII:85H0HZU99M)\\nPOVIDONE-IODINE\\n0.1 mL  in 1 mL\\nInactive Ingredients\\nIngredient Name\\nStrength","Certus Medical, Inc.\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nSODIUM PHOSPHATE, DIBASIC\\n (UNII: GR686LBA74)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nDIMETHICONE\\n (UNII: 92RU3N3Y1O)\\n \\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\n (UNII: S38J6RZN16)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:75990-4019-4\\n2 mL in 1 POUCH\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOT...","ABALONE CRYSTALDOUBLE EX CC- niacinamide, adenosine, titanium dioxide, ethylhexyl\\nmethoxycinnamate cream \\n \\nC&amp;BCOSMETIC Co.,Ltd.\\nDisclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been\\napproved by FDA. \\nFor further information about unapproved drugs, click here.\\n----------\\nDrug Facts\\nNiacinamide, Adenosine, Titanium Dioxide, Ethylhexyl Methoxycinnamate\\nWater, Glycerin, Butylene Glycol, Etc\\nSkin Protectant - Anti-Wrinkle, Whitening, UV Protecting\\nk...","ABALONE CRYSTALDOUBLE EX CC  \\nniacinamide, adenosine, titanium dioxide, ethylhexyl methoxycinnamate cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:60611-0008\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength","C&amp;BCOSMETIC Co.,Ltd.\\nNIACINAMIDE\\n (UNII: 25X51I8RD4) \\n(NIACINAMIDE - UNII:25X51I8RD4)\\nNIACINAMIDE\\n2 g  in 100 mL\\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP) \\n(TITANIUM DIOXIDE - UNII:15FIX9V2JP)\\nTITANIUM DIOXIDE\\n4.694 g  in 100 mL\\nADENOSINE\\n (UNII: K72T3FS567) \\n(ADENOSINE - UNII:K72T3FS567)\\nADENOSINE\\n0.04 g  in 100 mL\\nOCTINOXATE\\n (UNII: 4Y5P7MUD51) \\n(OCTINOXATE - UNII:4Y5P7MUD51)\\nOCTINOXATE\\n7 g  in 100 mL\\nInactive Ingredients\\nIngredient Name\\nStrength\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C...","TIZANIDINE HYDROCHLORIDE- tizanidine hydrochloride capsule \\n \\nAdvagen Pharma Limited\\n----------\\nHIGHLIGHTS OF PRESCRIBING INFORMATION\\nThese highlights do not include all the information needed to use TIZANIDINE\\nHYDROCHLORIDE CAPSULES safely and effectively. See full prescribing information for\\nTIZANIDINE HYDROCHLORIDE CAPSULES. \\nTIZANIDINE HYDROCHLORIDE capsules, for oral use\\n \\nInitial U.S. Approval: 1996\\nINDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indi...","Geriatric use: Tizanidine should be used with caution in elderly patients because clearance is decreased\\nfour-fold ( \\n8.5\\n)\\nSee 17 for PATIENT COUNSELING INFORMATION.\\nRevised: 9/2020\\nFULL PRESCRIBING INFORMATION: CONTENTS\\n*\\n1 INDICATIONS AND USAGE\\n2 DOSAGE AND ADMINISTRATION\\n2.1 Dosing Information\\n2.2 Dosing in Patients with Renal Impairment\\n2.3 Dosing in Patients with Hepatic Impairment\\n2.4 Drug Discontinuation\\n3 DOSAGE FORMS AND STRENGTHS\\n4 CONTRAINDICATIONS\\n5 WARNINGS AND PRECAUTIONS\\n5.1 Hypo...","12.1 Mechanism of Action\\n12.3 Pharmacokinetics\\n13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n14 CLINICAL STUDIES\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n16.1 Tizanidine Hydrochloride Capsules\\n17 PATIENT COUNSELING INFORMATION\\n*\\nFULL PRESCRIBING INFORMATION\\n1 INDICATIONS AND USAGE\\nTizanidine hydrochloride is a central alpha-2-adrenergic agonist indicated for the\\nmanagement of spasticity. Because of the short duration of therapeutic effect,\\ntreatment with tizanid...","been studied.\\n2.2 Dosing in Patients with Renal Impairment\\nTizanidine hydrochloride capsules should be used with caution in patients with renal\\ninsufficiency (creatinine clearance &lt; 25 mL/min), as clearance is reduced by more than\\n50%. In these patients, during titration, the individual doses should be reduced. If higher\\ndoses are required, individual doses rather than dosing frequency should be increased\\n[see Warnings and Precautions ( \\n5.7\\n)] \\n.\\n2.3 Dosing in Patients with Hepatic Impairment\\nT...","Tizanidine is an \\u03b1 \\n-adrenergic agonist that can produce hypotension. Syncope has been\\nreported in the post marketing setting. The chance of significant hypotension may\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\na supine to fixed upright position may be at increased risk for hypotension and\\northostatic effects.\\nMonitor for hypotension when tizanidine is used in patients...","Clinical Pharmacology ( \\n12.3\\n)]\\n5.6 Hypersensitivity Reactions\\nTizanidine can cause anaphylaxis. Signs and symptoms including respiratory\\ncompromise, urticaria, and angioedema of the throat and tongue have been reported.\\nPatients should be informed of the signs and symptoms of severe allergic reactions and\\ninstructed to discontinue tizanidine and seek immediate medical care should these signs\\nand symptoms occur. \\n[see Contraindications ( \\n4\\n)]\\n5.7 Increased Risk of Adverse Reactions in Patients...","264 patients received tizanidine and 261 patients received placebo. Across the three\\nstudies patient ages ranged from 15\\u201369 years and 51.4 percent were women. The\\nmedian dose during the plateau phase ranged from 20\\u201328 mg/day.\\nThe most frequent adverse reactions reported in multiple dose, placebo-controlled\\nclinical studies involving 264 patients with spasticity were dry mouth,\\nsomnolence/sedation, asthenia (weakness, fatigue and/or tiredness) and dizziness.\\nThree-quarters of the patients rated t...","multiple sclerosis (Study 1) \\n[see Clinical Studies ( \\n14\\n)] \\n, the patients were specifically\\nasked if they had experienced any of the four most common adverse reactions: dry\\nmouth, somnolence (drowsiness), asthenia (weakness, fatigue and/or tiredness) and\\ndizziness. In addition, hypotension and bradycardia were observed. The occurrence of\\nthese reactions is summarized in \\nTable 2\\n. Other events were, in general, reported at a\\nrate of 2% or less.\\nTable 2: Single Dose, Placebo-Controlled Study -...","Paresthesia\\nRash\\nTremor\\n7 DRUG INTERACTIONS\\n7.1 Fluvoxamine\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\npsychomotor impairment. \\n[see Contraindications ( \\n4\\n) and Clinical Pharmacology ( \\n12.3\\n)]\\n7.2 Ciprofloxacin\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\npharmacokinetics of ...","12.3\\n)]\\n7.7 \\u03b1 \\n-adrenergic agonists\\nBecause hypotensive effects may be cumulative, it is not recommended that tizanidine\\nbe used with other \\u03b1 \\n-adrenergic agonists. \\n[see Warnings and Precautions ( \\n5.1\\n)]\\n8 USE IN SPECIFIC POPULATIONS\\n8.1 Pregnancy\\nPregnancy Category C\\nTizanidine has not been studied in pregnant women. Tizanidine should be given to\\npregnant women only if the benefit outweighs the risk to the unborn fetus.\\nReproduction studies performed in rats at a dose of 3 mg/kg, equal to the...","8.6 Impaired Renal Function\\nTizanidine is known to be substantially excreted by the kidney, and the risk of adverse\\nreactions to this drug may be greater in patients with impaired renal function. In patients\\nwith renal insufficiency (creatinine clearance &lt; 25 mL/min) clearance was reduced by\\nmore than 50%. In these patients, during titration, the individual doses should be\\nreduced. If higher doses are required, individual doses rather than dosing frequency\\nshould be increased. These patients sho...","manifestations of tizanidine overdose were consistent with its known pharmacology. In\\nthe majority of cases a decrease in sensorium was observed including lethargy,\\nsomnolence, confusion and coma. Depressed cardiac function is also observed including\\nmost often bradycardia and hypotension. Respiratory depression is another common\\nfeature of tizanidine overdose.\\nShould overdose occur, basic steps to ensure the adequacy of an airway and the\\nmonitoring of cardiovascular and respiratory systems shou...","12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\nreduce facilitation of spinal motor neurons.\\n12.3 Pharmacokinetics\\nAbsorption and Distribution\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\n...","Metabolism and Excretion\\nTizanidine has linear pharmacokinetics over the doses studied in clinical development (1\\u2013\\n20 mg). Tizanidine has a half-life of approximately 2.5 hours (CV=33%). Approximately\\n95% of an administered dose is metabolized. The primary cytochrome P450 isoenzyme\\ninvolved in tizanidine metabolism is CYP1A2. Tizanidine metabolites are not known to be\\nactive; their half-lives range from 20 to 40 hours.\\nFollowing single and multiple oral dosing of \\nC-tizanidine, an average of 60%...","this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\nused with caution in renally impaired patients \\n[see Warnings and Precautions ( \\n5.7\\n) and\\nUse in Specific Populations ( \\n8.6\\n)] \\n.\\nGender Effects\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\npharmacokinetic...","13 NONCLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\nCarcinogenesis\\nTizanidine was administered to mice for 78 weeks at oral doses up to 16 mg/kg/day,\\nwhich is 2 times the maximum recommended human dose (MRHD) on a mg/m \\nbasis.\\nTizanidine was administered to rats for 104 weeks at oral doses up to 9 mg/kg/day,\\nwhich is 2.5 times the MRHD on a mg/m \\nbasis. There was no increase in tumors in\\neither species.\\nMutagenesis\\nTizanidine was negative in \\nin vitro\\n(bacterial r...","tone in placebo treated patients. Within a given patient, improvement in muscle tone was\\ncorrelated with plasma concentration. Plasma concentrations were variable from patient\\nto patient at a given dose. Although 16 mg produced a larger effect, adverse events\\nincluding hypotension were more common and more severe than in the 8 mg group.\\nThere were no differences in the number of spasms occurring in each group.\\nFigure 2: Single Dose Study - Mean Change in Muscle Tone from Baseline as\\nMeasured by ...","from baseline as measured by the Ashworth scale.\\nFigure 3: Seven Week Study - Mean Change in Muscle Tone 0.5-2.5 Hours\\nAfter Dosing as Measured by the Ashworth Scale \\u00b1 95% Confidence Interval\\n(A Negative Ashworth Score Signifies an Improvement in Muscle Tone from\\nBaseline)\\n16 HOW SUPPLIED/STORAGE AND HANDLING\\n16.1 Tizanidine Hydrochloride Capsules\\nTizanidine Hydrochloride Capsules are available in three strengths as two-piece hard\\ngelatin capsules containing tizanidine hydrochloride 2.29 mg, 4.5...","17 PATIENT COUNSELING INFORMATION\\nSerious Drug Interactions\\nAdvise patients they should not take tizanidine if they are taking fluvoxamine or\\nciprofloxacin because of the increased risk of serious adverse reactions including severe\\nlowering of blood pressure and sedation. Instruct patients to inform their physicians or\\npharmacists when they start or stop taking any medication because of the risks\\nassociated with interaction between tizanidine and other medicines.\\nTizanidine Dosing\\nTell patients ...","PRINCIPAL DISPLAY PANEL - 4 mg 150 Capsules Bottle - NDC 72888-002-15\\nPRINCIPAL DISPLAY PANEL - 6 mg 150 Capsules Bottle - NDC 72888-003-15","TIZANIDINE HYDROCHLORIDE  \\ntizanidine hydrochloride capsule\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:72888-001\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of\\nStrength\\nStrength\\nTIZANIDINE HYDROCHLORIDE\\n (UNII: B53E3NMY5C) \\n(TIZANIDINE -\\nUNII:6AI06C00GW)\\nTIZANIDINE\\n2 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nMICROCRYSTALLINE CELLULOSE 101\\n (UNII: 7T9FYH5QMK)\\n \\nLACTOSE MONOHYDRATE\\n (UNII: EWQ57Q8I5X)\\n \\nHYPROMELLOSE...","AMMONIA\\n (UNII: 5138Q19F1X)\\n \\nFERROSOFERRIC OXIDE\\n (UNII: XM0M87F357)\\n \\nPOTASSIUM HYDROXIDE\\n (UNII: WZH3C48M4T)\\n \\nProduct Characteristics\\nColor\\nblue (Cap: Blue opaque) , blue (Body: Light Blue opaque)\\nScore\\nno score\\nShape\\nCAPSULE\\nSize\\n11mm\\nFlavor\\nImprint Code\\nUpArrowhead;043\\nContains\\n    \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start\\nDate\\nMarketing End\\nDate\\n1\\nNDC:72888-001-\\n15\\n150 \\nin 1 BOTTLE; Type 0: Not a Combination\\nProduct\\n05/27/2020\\nMarketing Information\\nMarketing\\nCategory\\nAppl...","GELATIN, UNSPECIFIED\\n (UNII: 2G86QN327L)\\n \\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nFD&amp;C BLUE NO. 1\\n (UNII: H3R47K3TBD)\\n \\nFD&amp;C RED NO. 40\\n (UNII: WZB9127XOA)\\n \\nSHELLAC\\n (UNII: 46N107B71O)\\n \\nISOPROPYL ALCOHOL\\n (UNII: ND2M416302)\\n \\nPROPYLENE GLYCOL\\n (UNII: 6DC9Q167V3)\\n \\nALCOHOL\\n (UNII: 3K9958V90M)\\n \\nBUTYL ALCOHOL\\n (UNII: 8PJ61P6TS3)\\n \\nAMMONIA\\n (UNII: 5138Q19F1X)\\n \\nFERROSOFERRIC OXIDE\\n (UNII: XM0M87F357)\\n \\nPOTASSIUM HYDROXIDE\\n (UNII: WZH3C48M4T)\\n \\nProduct Characteristics\\nColor\\nblue (Cap: Blue opaque)...","Inactive Ingredients\\nIngredient Name\\nStrength\\nMICROCRYSTALLINE CELLULOSE 101\\n (UNII: 7T9FYH5QMK)\\n \\nLACTOSE MONOHYDRATE\\n (UNII: EWQ57Q8I5X)\\n \\nHYPROMELLOSE, UNSPECIFIED\\n (UNII: 3NXW29V3WO)\\n \\nSILICON DIOXIDE\\n (UNII: ETJ7Z6XBU4)\\n \\nCROSCARMELLOSE SODIUM\\n (UNII: M28OL1HH48)\\n \\nSTEARIC ACID\\n (UNII: 4ELV7Z65AP)\\n \\nGELATIN, UNSPECIFIED\\n (UNII: 2G86QN327L)\\n \\nTITANIUM DIOXIDE\\n (UNII: 15FIX9V2JP)\\n \\nFD&amp;C BLUE NO. 1\\n (UNII: H3R47K3TBD)\\n \\nFD&amp;C RED NO. 40\\n (UNII: WZB9127XOA)\\n \\nSHELLAC\\n (UNII: 46N107B71O)\\n \\nISOPRO...","Advagen Pharma Limited\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nRubicon Research\\nPrivate Limited\\n677604197\\nanalysis(72888-001, 72888-002, 72888-003) , manufacture(72888-001,\\n72888-002, 72888-003) , pack(72888-001, 72888-002, 72888-003)\\n \\nRevised: 7/2024","ATHLETES FOOT- butenafine hydrochloride cream \\n \\nRite Aid Corporation\\n----------\\nAthlete&#x27;s Foot Cream\\nDrug Facts\\nActive ingredient\\nButenafine hydrochloride 1%\\nPurpose\\nAntifungal\\nUses\\ncures most athlete&#x27;s foot between the toes. Effectiveness on the bottom or sides of\\nfoot is unknown.\\ncures most jock itch and ringworm\\nrelieves itching, burning, cracking, and scaling which accompany these conditions\\nWarnings\\nFor external use only\\nDo not use\\non nails or scalp\\nin or near the mouth or the eyes\\nfor vag...","1 week twice a day or 4 weeks once a day\\nfor jock itch and ringworm:\\napply once a day to affected skin for 2 weeks or as\\ndirected by a doctor.\\nwash hands after each use\\nchildren under 12 years: ask a doctor\\nOther information\\ndo not use if seal on tube is broken or not visible\\nstore between 20\\u00ba to 25\\u00ba C (68\\u00ba to 77\\u00ba F)\\nInactive ingredients\\nbenzyl alcohol, cetyl alcohol, glycerin, glyceryl monostearate SE, polyoxyethylene (23)\\ncetyl ether, propylene glycol dicaprylate, purified water, sodium benzoa...","RITE \\nAID \\n \\nPHARMACY\\nclinically proven to cure \\nmost athlete&#x27;s foot between the toes\\nfoot care \\nbutenafine\\nhydrochloride cream 1%\\nantifungal\\nNET WT 0.42 OZ (12 g)\\n\\u00ae","ATHLETES FOOT  \\nbutenafine hydrochloride cream\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:11822-2100\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nBUTENAFINE HYDROCHLORIDE\\n (UNII: R8XA2029ZI) \\n(BUTENAFINE -\\nUNII:91Y494NL0X)\\nBUTENAFINE\\nHYDROCHLORIDE\\n10 mg\\n in 1 g\\nInactive Ingredients\\nIngredient Name\\nStrength\\nBENZYL ALCOHOL\\n (UNII: LKG8494WBH)\\n \\nCETYL ALCOHOL\\n (UNII: 936JST6JCN)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n...","Rite Aid Corporation\\nMarketing Information\\nMarketing\\nCategory\\nApplication Number or Monograph\\nCitation\\nMarketing Start\\nDate\\nMarketing End\\nDate\\nANDA\\nANDA205181\\n11/17/2017\\nLabeler - \\nRite Aid Corporation \\n(014578892)\\nEstablishment\\nName\\nAddress\\nID/FEI\\nBusiness Operations\\nTaro Pharmaceuticals Inc.\\n206263295\\nmanufacture(11822-2100)\\n \\nRevised: 7/2024"]],["color",{"type":"ndarray","array":["#ffbb78","#ffbb78","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#aec7e8","#999","#999","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#ff7f0e","#999","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#aec7e8","#999","#aec7e8","#aec7e8","#ffbb78","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#2ca02c","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#1f77b4","#ffbb78","#999","#ffbb78","#ffbb78","#ffbb78","#999","#ffbb78","#ffbb78","#ffbb78","#ffbb78","#ffbb78"],"shape":[117],"dtype":"object","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1777","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1778"}}},"glyph":{"type":"object","name":"Scatter","id":"p1773","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1774","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1775","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1744","attributes":{"logo":"grey","tools":[{"type":"object","name":"HoverTool","id":"p1759","attributes":{"renderers":"auto","tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Document Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}},{"type":"object","name":"PanTool","id":"p1760"},{"type":"object","name":"WheelZoomTool","id":"p1761","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1762","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1763","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1768"},{"type":"object","name":"SaveTool","id":"p1769"}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1754","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1755","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1756"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1757"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1749","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1750","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1751"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1752"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1753","attributes":{"axis":{"id":"p1749"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1758","attributes":{"dimension":1,"axis":{"id":"p1754"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1779","attributes":{"title":"Knowledge Base Tospics","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1780","attributes":{"label":{"type":"value","value":"ACE Inhibitors"},"renderers":[{"id":"p1776"}],"index":31}},{"type":"object","name":"LegendItem","id":"p1781","attributes":{"label":{"type":"value","value":"Candesartan Cilexetil"},"renderers":[{"id":"p1776"}],"index":62}},{"type":"object","name":"LegendItem","id":"p1782","attributes":{"label":{"type":"value","value":"Medication Information"},"renderers":[{"id":"p1776"}],"index":2}},{"type":"object","name":"LegendItem","id":"p1783","attributes":{"label":{"type":"value","value":"Others"},"renderers":[{"id":"p1776"}],"index":25}},{"type":"object","name":"LegendItem","id":"p1784","attributes":{"label":{"type":"value","value":"Pharmaceutical Products"},"renderers":[{"id":"p1776"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1785","attributes":{"label":{"type":"value","value":"Tizanidine Overdose"},"renderers":[{"id":"p1776"}],"index":87}}]}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}},{"type":"object","name":"TabPanel","id":"p1855","attributes":{"title":"Failures","child":{"type":"object","name":"Figure","id":"p1791","attributes":{"sizing_mode":"stretch_width","x_range":{"type":"object","name":"Range1d","id":"p1800","attributes":{"start":2.6081478595733643,"end":17.234113693237305}},"y_range":{"type":"object","name":"Range1d","id":"p1801","attributes":{"start":13.671540260314941,"end":21.66947841644287}},"x_scale":{"type":"object","name":"LinearScale","id":"p1802"},"y_scale":{"type":"object","name":"LinearScale","id":"p1803"},"title":{"type":"object","name":"Title","id":"p1798","attributes":{"text_color":"#E0E0E0","text_font":"Helvetica","text_font_size":"14pt"}},"outline_line_color":"#E0E0E0","outline_line_alpha":0.25,"renderers":[{"type":"object","name":"GlyphRenderer","id":"p1830","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1787","attributes":{"selected":{"type":"object","name":"Selection","id":"p1788","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1789"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"2D/VQDIDEUG5uDZBUwLvQM/ef0D+0w5Bd7uRQHzWp0Bv3zZBLaQtQSIikUBnbaVA8/oVQd8AFUENH1NAoNsJQVC6xUCdjBpBYsAuQR1C+UAYsp5A3bhaQGgizkADdxBBDS0JQQ=="},"shape":[25],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"4xd9Qd5zoEFiB5BB0aWFQYmLjkGnmY1Bs1qPQWHzkUFE9olBSpKOQViHlUGV/3hB/leeQQb/mEGAZ4xBMwiGQXdQjEHrP51BlNCRQQA+g0GbuHJBlemOQXHniUGZN5dBC0aiQQ=="},"shape":[25],"dtype":"float32","order":"little"}],["topic",["Others","NUCYNTA\\u2122 Medication","Tizanidine Hydrochloride","Povidone Iodine Solution","ACE Inhibitor Side Effects","Others","ACE Inhibitor Side Effects","ACE Inhibitor Side Effects","Tizanidine Hydrochloride","Tizanidine Hydrochloride","ACE Inhibitor Side Effects","Candesartan Cilexetil","NUCYNTA\\u2122 Medication","NUCYNTA\\u2122 Medication","ACE Inhibitor Side Effects","Povidone Iodine Solution","ACE Inhibitor Side Effects","NUCYNTA\\u2122 Medication","Tizanidine Hydrochloride","Pharmaceuticals","Candesartan Cilexetil","ACE Inhibitor Side Effects","Others","NUCYNTA\\u2122 Medication","NUCYNTA\\u2122 Medication"]],["correctness",[false,false,true,true,false,false,false,true,false,false,true,false,false,false,false,false,false,true,false,false,false,false,false,false,false]],["questions",["What specific advantages does hydrochlorothiazide offer in the tablets containing candesartan cilexetil, and what are the strengths of hydrochlorothiazide in each of the different tablet formulations?","What is the abuse potential of NUCYNTA\\u2122, how is it classified, and what precautions should be taken for patients with hepatic impairment?","How does the consumption of alcohol impact the pharmacokinetics of tizanidine, specifically in terms of its area under the curve (AUC) and maximum concentration (Cmax)?","What are the specific active ingredients present in the GRX DYNE povidone iodine solution and what is the concentration of the active ingredient in the solution?","What are the most frequently reported clinical adverse experiences in trials involving lisinopril and hydrochlorothiazide tablets, and what precautions should be taken into account when considering the drug&#x27;s use in nursing mothers?","What are the different strengths available for tapentadol hydrochloride medication and what are the corresponding colors of the tablets?","What is the specific mechanism by which hydrochlorothiazide exerts its antihypertensive effect, and how does it impact the electrolyte reabsorption mechanism in the distal renal tubule?","What are the available strengths of lisinopril and hydrochlorothiazide tablets, and how are they supplied?","Can you explain the difference in bioavailability between Tizanidine Capsules and Tizanidine Tablets, particularly when administered with food, and how does it impact the peak plasma concentration and time to peak plasma concentration?","What specific parameter should be monitored in patients taking tizanidine to mitigate the risk of hepatocellular liver injury, especially in those with hepatic impairment?","In the case of hypotension resulting from an overdose of Lisinopril, what is the recommended treatment involving the administration of what type of solution?","How does candesartan impact the pressor effects of angiotensin II infusion, and to what extent is this effect inhibited by the medication?","What specific type of surgery was conducted to assess the effectiveness of NUCYNTA\\u2122 in the clinical trial mentioned in the document?","Can you provide a list of psychiatric disorders that are mentioned as potential adverse reactions to NUCYNTA\\u2122, according to the provided document?","What clinical signs should patients undergoing thiazide therapy be monitored for in terms of fluid and electrolyte imbalance, and what are some specific warning signs or symptoms that may indicate such an imbalance?","What is the specific active component found in the foot care cream designed to treat athlete&#x27;s foot located between the toes?","What is the strength of Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07?","What is the average duration of the terminal half-life of tapentadol following oral administration, and how does it compare in subjects with varying degrees of renal function?","What are the specific contraindications for the simultaneous use of tizanidine with fluvoxamine and ciprofloxacin, and what potential effects on blood pressure, drowsiness, and psychomotor impairment should be considered?","When did the marketing of the product with NDC:75990-4019-4 officially begin according to the provided document?","What are the potential manifestations of overdosage with candesartan cilexetil, and what supportive treatment should be initiated if symptomatic hypotension occurs?","What are the potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy, specifically in terms of fetal renal function, morbidity, and mortality?","What are the specific strengths of lisinopril and hydrochlorothiazide in the tablets with NDC:69097-969, and what are the color and shape of these tablets?","How should the dosing regimen for NUCYNTA (tapentadol) be adjusted to maintain adequate pain relief with acceptable tolerability?","What are some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\u2122, including symptoms such as disturbance in attention, sedation, dysarthria, and ataxia?"]],["agent_answer",["Great question about the combination tablets containing **candesartan cilexetil and hydrochlorothiazide (HCTZ)**! This combination is commonly used for **hypertension (high blood pressure)**, leveraging the complementary mechanisms of both drugs. Let me break it down clearly:\\n\\n### **1. Advantages of Hydrochlorothiazide in this Combination:**\\n- **Synergistic Blood Pressure Control**: Candesartan (an **ARB**) reduces blood pressure by blocking angiotensin II receptors, while **HCTZ (a thiazide diuretic)** enhances fluid and sodium excretion via the kidneys. Together, they provide **dual-action** lowering of blood pressure more effectively than either drug alone.  \\n- **Volume Reduction**: HCTZ counterbalances potential fluid retention (a rare side effect of ARBs) by promoting **diuresis**, ensuring better BP control.  \\n- **Lower Dosing Needs**: The combination allows for **lower doses** of each drug compared to monotherapy, reducing the risk of side effects.  \\n\\n### **2. Strengths of Hydrochlorothiazide in Different Tablet Formulations:**\\nThe combined tablets typically come in the following strengths (candesartan cilexetil / HCTZ):\\n\\n- **16 mg / 12.5 mg**  \\n  - **HCTZ Strength**: 12.5 mg (moderate diuretic effect, suitable for mild hypertension).  \\n- **32 mg / 12.5 mg**  \\n  - **HCTZ Strength**: 12.5 mg (same diuretic effect but paired with a higher ARB dose for enhanced BP lowering).  \\n- **32 mg / 25 mg**  \\n  - **HCTZ Strength**: 25 mg (stronger diuretic effect for patients needing more fluid removal).  \\n\\n### **Key Point on Hydrochlorothiazide Strengths:**\\n- **12.5 mg HCTZ** \\u2192 Balanced diuresis, ideal for patients who need mild to moderate fluid loss.  \\n- **25 mg HCTZ** \\u2192 Stronger effect, useful in those requiring **greater sodium/fluid excretion** or with resistant hypertension.  \\n\\nWould you like additional details on dosing adjustments or patient-specific considerations? Happy to help further!","**NUCYNTA\\u2122 (tapentadol) Abuse Potential, Classification, and Hepatic Impairment Precautions:**  \\n\\n### **1. Abuse Potential**  \\nNUCYNTA\\u2122 (tapentadol) is an opioid analgesic with **significant abuse potential**, similar to other opioids like oxycodone or morphine. Its mechanism involves **\\u03bc-opioid receptor agonism** (though weaker than traditional opioids) and **noradrenaline reuptake inhibition**, which contributes to its pain-relieving effects but also poses addiction risks.  \\n\\n- **Misuse can lead to:**  \\n  - Psychological dependence  \\n  - Physical dependence (withdrawal symptoms upon discontinuation)  \\n  - Overdose (respiratory depression, sedation, death)  \\n- **Common routes of abuse:** Oral (crushed tablets), nasal insufflation, or intravenous injection.  \\n\\n### **2. Controlled Substance Classification (U.S.)**  \\n- NUCYNTA\\u2122 is classified as a **Schedule II controlled substance** under the U.S. Controlled Substances Act (CSA).  \\n- This reflects its **high abuse potential** but also recognized medical use.  \\n\\n### **3. Precautions for Hepatic Impairment**  \\nSince tapentadol is extensively metabolized by the liver (~95% via glucuronidation), hepatic impairment affects its pharmacokinetics:  \\n\\n- **Mild hepatic impairment (Child-Pugh A):**  \\n  - Initiate at **50 mg** (instead of 50\\u2013100 mg for adults).  \\n  - Maximum dosing interval: **\\u2264 50 mg every 6 hours** (max 200 mg/day).  \\n- **Moderate hepatic impairment (Child-Pugh B):**  \\n  - **Avoid or use extreme caution**\\u2014dose reduction likely needed (no strict guidelines, but start at **lower than 50 mg**).  \\n- **Severe hepatic impairment (Child-Pugh C):**  \\n  - **Contraindicated** due to high risk of **toxicity accumulation**.  \\n\\n#### **Additional Monitoring Recommendations:**  \\n- Look for signs of **opioid toxicity** (sedation, respiratory depression).  \\n- Avoid **concomitant CYP enzyme inhibitors/inducers** that may alter metabolism.  \\n\\n### **Conclusion**  \\nNUCYNTA\\u2122 should be prescribed cautiously, with strict adherence to dosing adjustments in liver dysfunction and monitoring for abuse behaviors. Alternative analgesics may be considered in severe hepatic impairment.  \\n\\nWould you like additional details on its pharmacokinetics or withdrawal management?","Great question! The consumption of alcohol can significantly impact the pharmacokinetics of tizanidine, particularly its **AUC (area under the curve)** and **Cmax (maximum concentration)**. Here\\u2019s what we know:  \\n\\n### **1. Alcohol and Tizanidine Pharmacokinetics**  \\n- Alcohol is a **CYP1A2 inhibitor**, the same enzyme primarily responsible for metabolizing tizanidine.  \\n- When alcohol and tizanidine are co-administered, tizanidine&#x27;s metabolism is slowed, leading to:  \\n  - **\\u2191 AUC**: A higher total systemic exposure (AUC increases by ~20\\u201330%).  \\n  - **\\u2191 Cmax**: A higher peak plasma concentration (Cmax increases by ~15\\u201325%).  \\n\\n### **2. Mechanism**  \\n- Alcohol temporarily **inhibits CYP1A2**, decreasing tizanidine\\u2019s metabolism and prolonging its half-life.  \\n- This results in **increased plasma concentrations** of tizanidine, enhancing its sedative and hypotensive effects.  \\n\\n### **3. Clinical Implications**  \\n- Combining alcohol with tizanidine **intensifies side effects**, including:  \\n  - Severe drowsiness  \\n  - Dizziness  \\n  - Hypotension (low blood pressure)  \\n  - Risk of respiratory depression (in extreme cases)  \\n\\n### **Official Recommendations**  \\n- **FDA and medical guidelines strongly advise against alcohol consumption** while using tizanidine due to the risk of **toxicity** and amplified CNS depression.  \\n\\n### **Conclusion**  \\n- Alcohol significantly **\\u2191 AUC &amp; Cmax** of tizanidine by inhibiting CYP1A2.  \\n- This interaction increases both **therapeutic effects and risks**, making alcohol contraindicated with tizanidine.  \\n\\nNeed any more details? Happy to expand!  \\ud83d\\ude80","Certainly! Here\\u2019s a detailed breakdown of the active ingredient in **GRX DYNE Povidone Iodine Solution** and its concentration:\\n\\n### **Active Ingredient**:  \\nThe primary active ingredient in GRX DYNE Povidone Iodine Solution is **Povidone-Iodine (PVP-I)**, a complex of **iodine** with **polyvinylpyrrolidone (povidone)**.  \\n\\n### **Concentration of Active Ingredient**:  \\nThe standard concentration of **available iodine** (the effective antimicrobial component) in povidone-iodine solutions is typically **10% w/v (weight/volume)**.  \\n\\n- This means **10 grams of povidone-iodine complex per 100 mL of solution**.  \\n- Of this, the **available (free) iodine** concentration is about **1% (10,000 ppm)**.  \\n\\n### **Additional Notes**:  \\n- **Mechanism**: Povidone-iodine acts as a broad-spectrum antiseptic, effective against bacteria, viruses, fungi, and protozoa by releasing free iodine.  \\n- **Common Uses**: Surgical scrubs, wound disinfection, and pre-operative skin preparation.  \\n\\nIf you&#x27;re looking for the *exact* concentration in GRX DYNE\\u2019s formulation (which may have slight variations), I recommend checking the **product label** or the manufacturer\\u2019s technical datasheet for precise details.  \\n\\nWould you like any further details on its applications or safety precautions?","Great question! Let me break this down into two key parts for clarity.\\n\\n### **Most Frequently Reported Clinical Adverse Experiences with Lisinopril/Hydrochlorothiazide (HCTZ) Tablets**  \\nBased on clinical trials and post-marketing data, the most common adverse effects include:  \\n\\n1. **Respiratory**:  \\n   - Cough (ACE inhibitor-associated, more common with lisinopril)  \\n   - Upper respiratory infections  \\n\\n2. **Cardiovascular**:  \\n   - Dizziness (due to hypotension, especially in volume-depleted patients)  \\n   - Orthostatic hypotension  \\n\\n3. **Metabolic/Electrolyte Disturbances** (mainly due to HCTZ):  \\n   - Hypokalemia (low potassium)  \\n   - Hyponatremia (low sodium)  \\n   - Hyperuricemia (can exacerbate gout)  \\n   - Hyperglycemia (may worsen diabetes)  \\n\\n4. **Gastrointestinal**:  \\n   - Nausea/diarrhea (more common early in therapy)  \\n\\n5. **Dermatological**:  \\n   - Rash (sometimes photosensitivity due to HCTZ)  \\n\\n6. **Renal**:  \\n   - Increased serum creatinine (risk higher in renal impairment)  \\n\\n*Severe but less common*: Angioedema (ACE inhibitor-related), acute kidney injury, electrolyte imbalances (\\u2191Ca\\u00b2\\u207a, \\u2193Mg\\u00b2\\u207a), and severe hypotension.  \\n\\n---\\n\\n### **Precautions in Nursing Mothers**  \\n- **Lisinopril (ACE inhibitor)**:  \\n  - **Excreted in breast milk?** Yes, though in small amounts.  \\n  - **Potential risk**: Hypotension, hyperkalemia, or renal effects in the infant.  \\n  - **Precaution**: Avoid breastfeeding if possible; consider alternative antihypertensives (e.g., labetalol or nifedipine, which have better safety profiles). If used, monitor infant for lethargy, poor feeding, or hypotension.  \\n\\n- **Hydrochlorothiazide (HCTZ)**:  \\n  - **Excreted in breast milk?** Yes, though low concentrations.  \\n  - **Potential risk**: Suppressed lactation (thiazides reduce milk volume), possible electrolyte imbalances (hypokalemia), or thrombocytopenia in the infant.  \\n  - **Precaution**: Generally **contraindicated** during breastfeeding due to these risks. Switch to a safer diuretic (e.g., chlorthalidone may be considered in some cases) or a non-diuretic alternative.  \\n\\n---\\n\\n### **Key Recommendation**:  \\nThe *American Academy of Pediatrics* (AAP) discourages ACE inhibitors and thiazides in nursing mothers when safer alternatives exist. A **shared decision-making approach** with the healthcare provider is critical to weigh benefits vs. infant risks.  \\n\\nWould you like references to specific studies or guidelines? I can provide those as well!","Here\\u2019s a detailed breakdown of the available strengths and corresponding colors of **tapentadol hydrochloride** tablets, which are commonly prescribed for moderate to severe pain:  \\n\\n### **Immediate-Release Tablets (e.g., Nucynta\\u00ae):**  \\n- **50 mg**: Light orange, round, film-coated, imprinted with \\u201cO-M\\u201d on one side and \\u201c50\\u201d on the other.  \\n- **75 mg**: Light yellow, round, film-coated, imprinted with \\u201cO-M\\u201d on one side and \\u201c75\\u201d on the other.  \\n- **100 mg**: Light blue, round, film-coated, imprinted with \\u201cO-M\\u201d on one side and \\u201c100\\u201d on the other.  \\n\\n### **Extended-Release Tablets (e.g., Nucynta ER\\u00ae):**  \\n- **50 mg**: Light orange, oval-shaped, film-coated, imprinted with \\u201cOMJ 50\\u201d on one side.  \\n- **100 mg**: Light blue, oval-shaped, film-coated, imprinted with \\u201cOMJ 100\\u201d on one side.  \\n- **150 mg**: Light green, oval-shaped, film-coated, imprinted with \\u201cOMJ 150\\u201d on one side.  \\n- **200 mg**: Light blue-green, oval-shaped, film-coated, imprinted with \\u201cOMJ 200\\u201d on one side.  \\n- **250 mg**: Light purple, oval-shaped, film-coated, imprinted with \\u201cOMJ 250\\u201d on one side.  \\n\\n### **Key Notes:**  \\n- **Colors and imprints** may vary slightly depending on the manufacturer (brand vs. generic).  \\n- These formulations are **controlled substances** (Schedule II in the U.S.) due to their opioid component.  \\n- Always **verify with the pharmacist** if you have doubts about the medication\\u2019s appearance to ensure correct dosing.  \\n\\nWould you like additional details on usage, precautions, or side effects? I\\u2019d be happy to assist!","Great question! Let me break down the mechanism of hydrochlorothiazide (HCTZ) in detail:\\n\\n**Antihypertensive Effect Mechanism:**\\n1. **Primary Action:** HCTZ is a thiazide diuretic that works by inhibiting the **Na+-Cl- symporter (NCC)** in the **early distal convoluted tubule (DCT)** of the nephron.  \\n2. **Electrolyte Reabsorption Impact:**  \\n   - By blocking NCC, it reduces the reabsorption of **sodium (Na+)** and **chloride (Cl-)** ions, leading to increased excretion of these electrolytes in urine.  \\n   - This creates an osmotic gradient, pulling water into the tubule (diuresis), reducing blood volume \\u2192 lowering blood pressure.  \\n3. **Secondary Effects:**  \\n   - The reduced Na+ reabsorption in the DCT causes **compensatory increased Na+ reabsorption** in the collecting duct via **ENaC (epithelial sodium channels)**.  \\n   - However, this also leads to **potassium (K+) secretion** via ROMK channels, causing **hypokalemia** (a common side effect).  \\n\\n**Electrolyte-Specific Effects:**  \\n- **Calcium (Ca2+):** HCTZ paradoxically **enhances Ca2+ reabsorption** by increasing basolateral Na+/Ca2+ exchange due to decreased intracellular Na+ in the DCT. This can lead to *mild hypercalcemia*.  \\n- **Magnesium (Mg2+):** Thiazides reduce Mg2+ reabsorption (via TRPM6 channels), sometimes causing *hypomagnesemia*.  \\n- **Uric Acid:** Reduced tubular secretion of uric acid may cause *hyperuricemia* (gout risk).  \\n\\n**Long-Term Antihypertensive Effect:**  \\nBeyond diuresis, HCTZ reduces peripheral vascular resistance (PVR) by unclear mechanisms\\u2014possibly involving **vasodilatory prostaglandins** or **calcium channel modulation** in smooth muscle.  \\n\\n**Key Takeaways:**  \\n- **Target:** NCC in early DCT \\u2192 Na+/Cl- excretion.  \\n- **Major Side Effects:** Hypokalemia, hypercalcemia, hypomagnesemia.  \\n- **Net Result:** Reduced blood volume &amp; PVR \\u2192 sustained BP lowering.  \\n\\nLet me know if you\\u2019d like deeper details on any part!","Lisinopril and hydrochlorothiazide tablets are available in several fixed-dose combination strengths, commonly prescribed for hypertension (high blood pressure). Here\\u2019s a breakdown of the available strengths and how they are typically supplied:  \\n\\n### **Available Strengths:**  \\nThese combinations are expressed as **lisinopril (mg) / hydrochlorothiazide (mg)**:  \\n1. **10/12.5 mg**  \\n2. **20/12.5 mg**  \\n3. **20/25 mg**  \\n\\n### **How They Are Supplied:**  \\n- **Tablets:** The most common form, usually oval or round, with distinct markings (e.g., imprints for identification).  \\n- **Packaging:** Typically supplied in bottles (e.g., 30, 90, or 100 tablets) or blister packs (unit doses for compliance aids).  \\n- **Colors &amp; Markings:** Vary by manufacturer but often follow standard identifiers (e.g., \\"10/12.5\\" might be a white tablet with \\"AC295\\" imprinted).  \\n\\n### **Notes:**  \\n- Always confirm the exact dose with the prescribing physician, as strengths differ for individual patient needs.  \\n- Some brands or generics may have slight variations in appearance, but the active ingredients remain consistent.  \\n\\nWould you like details on specific manufacturers or alternatives? I\\u2019d be happy to refine the answer further!","Certainly! Let&#x27;s break down the differences in bioavailability between **Tizanidine capsules** and **Tizanidine tablets**, especially when administered with food, and how these differences impact **peak plasma concentration (C_max)** and **time to peak plasma concentration (T_max)**.\\n\\n### **1. Bioavailability Differences Between Capsules &amp; Tablets**\\n- **Tizanidine Capsules**: Typically have **higher bioavailability** (~20\\u201340%) compared to tablets due to differences in formulation (e.g., lipid-based or optimized dissolution properties).\\n- **Tizanidine Tablets**: Exhibit **lower bioavailability** (~20\\u201330%) as they rely on conventional disintegration and absorption mechanisms.\\n\\n### **2. Effect of Food on Bioavailability**\\n- **Tizanidine Capsules with Food**:  \\n  - **Increased absorption**: Fatty meals enhance bioavailability by **30\\u201350%**, increasing **C_max** (higher peak concentration).  \\n  - **Delayed T_max**: Food slows gastric emptying, delaying peak concentration (e.g., **T_max ~2\\u20133 hours** vs. fasting **~1\\u20131.5 hours**).  \\n  - **Reduced inter-individual variability**: More predictable absorption compared to fasting state.\\n  \\n- **Tizanidine Tablets with Food**:  \\n  - **Less pronounced impact**: Unlike capsules, food does not significantly enhance absorption in tablets (bioavailability increase ~10\\u201320%).  \\n  - **T_max delay similar to capsules** (but with lower **C_max** due to lower intrinsic absorption efficiency).\\n\\n### **3. Comparative Summary**\\n| Parameter               | Tizanidine Capsules | Tizanidine Tablets |\\n|-------------------------|---------------------|---------------------|\\n| **Fast-state C_max**    | Moderate (lower than fed) | Moderate (slightly lower than capsules) |\\n| **Fed-state C_max**     | **Significantly higher (~30\\u201350%)** | **Minimal increase (~10\\u201320%)** |\\n| **T_max (fasted)**      | **1\\u20131.5 hours**      | **1\\u20132 hours**       |\\n| **T_max (with food)**   | **2\\u20133 hours**        | **2\\u20133 hours**       |\\n| **Bioavailability (fasted)** | ~20\\u201340% | ~20\\u201330% |\\n| **Bioavailability (fed)** | **30\\u201350%** | **20\\u201335%** |\\n\\n### **4. Clinical Implications**\\n- **Capsules + Food = Stronger Effect**: Due to higher **C_max**, may require dose adjustments to avoid excessive sedation/hypotension.  \\n- **Tablets + Food = More Stable**: Predictable absorption, but less affected by food; may be preferable for controlled dosing.  \\n- **Morning vs. Night Dosing**: If taking with meals, **C_max delay (3h)** may influence sedation timing (e.g., bedtime vs. daytime dosing).  \\n\\n### **Conclusion**\\n**Capsules** show **greater food-enhanced bioavailability**, leading to higher **C_max** and a delayed **T_max**, while **tablets** are less affected. Clinicians should consider:\\n- **Pill formulation**  \\n- **Dosing with/without food**  \\n- **Timing of side effects (C_max-related sedation)**  \\n\\nWould you like a deeper dive into pharmacokinetic mechanisms or dosing recommendations?","Great question! For patients taking **tizanidine (a muscle relaxant)**, especially those with **pre-existing hepatic impairment**, the key parameter that should be closely monitored is:  \\n\\n### **Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) Levels**  \\n\\n#### **Why These Parameters?**  \\n- Tizanidine is **primarily metabolized in the liver** via CYP1A2.  \\n- Elevated **ALT/AST** levels can indicate **hepatocellular injury** (a known but rare side effect of tizanidine).  \\n- **Liver function tests (LFTs)**, including ALT, AST, **bilirubin, and alkaline phosphatase (ALP)**, should be done:  \\n  - **Before initiating therapy** (baseline).  \\n  - **Periodically thereafter** (e.g., within the first 6 months, then as clinically indicated).  \\n\\n#### **Additional Monitoring for High-Risk Patients**  \\nFor patients with **known hepatic impairment**:  \\n- **Reduced dosages** are usually necessary (due to slowed metabolism).  \\n- **More frequent LFT monitoring** is recommended (e.g., monthly or as per physician discretion).  \\n- Symptoms of liver injury (jaundice, dark urine, fatigue, abdominal pain) should prompt **immediate discontinuation** and liver function reassessment.  \\n\\n#### **FDA &amp; Clinical Guidelines**  \\n- The **FDA label for tizanidine** highlights the risk of **liver enzyme elevations** (ALT &gt;3x upper limit of normal in ~5% of patients in trials).  \\n- **Discontinue if ALT/AST &gt;3x ULN** (upper limit of normal) to prevent progression to severe liver injury.  \\n\\nWould you like any further details on dosing adjustments or alternative monitoring strategies?","In the case of **hypotension resulting from an overdose of Lisinopril** (an ACE inhibitor), the recommended treatment involves **intravenous (IV) administration of normal saline (0.9% sodium chloride solution)**. This is the first-line therapy to restore intravascular volume and counteract the hypotension caused by vasodilation and reduced systemic vascular resistance due to excessive ACE inhibition.  \\n\\nAdditional supportive measures may include:  \\n- **Trendelenburg positioning** (raising the patient\\u2019s legs to improve venous return).  \\n- **Vasopressors** (e.g., norepinephrine) if hypotension persists despite fluid resuscitation.  \\n- **Atropine** for severe bradycardia (if present).  \\n- **Hemodialysis** in extreme cases (since Lisinopril is partially dialyzable).  \\n\\n**Key rationale for normal saline:**  \\nLisinopril-induced hypotension is primarily due to decreased angiotensin II production, leading to venous/arterial dilation and reduced blood pressure. Normal saline helps restore plasma volume, improving cardiac preload and perfusion.  \\n\\nWould you like further details on dosing or clinical monitoring in this scenario?","Great question! Let me break this down for you clearly and completely:\\n\\n**How Candesartan Impacts Angiotensin II Pressor Effects:**\\nCandesartan is an ARB (angiotensin II receptor blocker) that selectively blocks the AT\\u2081 receptor subtype. When angiotensin II is infused, its pressor (blood pressure-raising) effects occur primarily through AT\\u2081 receptor activation in vascular smooth muscle. Candesartan competitively inhibits this binding.\\n\\n**Degree of Inhibition:**\\nClinical studies show:\\n1. At standard doses (8-32 mg daily), candesartan inhibits ~70-85% of angiotensin II&#x27;s pressor response.\\n2. The inhibition is dose-dependent - higher doses achieve greater receptor blockade.\\n3. Maximal inhibition typically occurs within 3-4 hours post-dose and lasts 24+ hours (due to candesartan&#x27;s tight receptor binding and long half-life).\\n4. Unlike ACE inhibitors, ARBs like candesartan don&#x27;t affect bradykinin metabolism, making the inhibition specific to the angiotensin pathway.\\n\\n**Key Mechanisms:**\\n- Prevents AT\\u2081-mediated vasoconstriction\\n- Blocks angiotensin II-induced aldosterone secretion\\n- Reduces\\u4ea4\\u611f\\u795e\\u7ecf\\u5174\\u594b\\u6027(sympathetic activation)\\n\\n**Important Notes:**\\n\\u2022 The remaining ~15-30% of pressor activity may occur via unblocked AT\\u2081 receptors or alternative pathways (like AT\\u2082 receptors in some conditions).\\n\\u2022 Patients may show individual variability in response based on genetics, sodium status, and baseline RAAS activity.\\n\\nWould you like me to elaborate on any particular aspect of this mechanism or the clinical studies demonstrating these effects?","The document states that the clinical trial assessing the effectiveness of NUCYNTA\\u2122 (tapentadol) involved patients undergoing **bunionectomy surgery** (a common foot surgery to correct bunions). This specific type of surgery was chosen as a standardized, moderate-to-severe pain model to evaluate the drug&#x27;s efficacy in acute post-operative pain management.  \\n\\nLet me know if you&#x27;d like additional details about the trial design or outcomes!","Certainly! Below is a list of psychiatric disorders identified as potential adverse reactions to NUCYNTA\\u2122 (tapentadol), according to the prescribing information:  \\n\\n### **Psychiatric Adverse Reactions Associated with NUCYNTA\\u2122:**  \\n- **Anxiety**  \\n- **Depression**  \\n- **Hallucinations**  \\n- **Confusion**  \\n- **Insomnia** (sleep disturbances)  \\n- **Abnormal dreams/nightmares**  \\n- **Nervousness**  \\n- **Euphoria** (elevated mood)  \\n- **Agitation**  \\n- **Decreased libido**  \\n\\nThese reactions may occur in some patients, particularly with prolonged use or higher doses. If you or someone you know experiences these symptoms while taking NUCYNTA\\u2122, it\\u2019s important to consult a healthcare provider.  \\n\\nLet me know if you&#x27;d like details on frequency (e.g., common vs. rare) or additional safety considerations.","Great question! Patients undergoing thiazide diuretic therapy should be closely monitored for **fluid and electrolyte imbalances**, as these medications can significantly impact hydration and key electrolytes. Here\\u2019s what to look for:\\n\\n### **Fluid Imbalance**  \\nThiazides promote diuresis (increased urine output), which can lead to:  \\n- **Hypovolemia/dehydration**:  \\n  - **Signs/symptoms**: Dry mouth, excessive thirst, dizziness, fatigue, low blood pressure (especially orthostatic hypotension), dark or concentrated urine, and reduced skin turgor (elasticity).  \\n\\n### **Electrolyte Imbalances**  \\n1. **Hypokalemia (Low Potassium)**:  \\n   - **Warning signs**: Muscle weakness, cramps, fatigue, palpitations, arrhythmias, and constipation. Severe cases may lead to paralysis or life-threatening arrhythmias.  \\n   - **Risk factors**: Higher in patients with poor dietary potassium intake, on high-dose thiazides, or with concomitant steroid use.  \\n\\n2. **Hyponatremia (Low Sodium)**:  \\n   - **Symptoms**: Headache, confusion, nausea, lethargy, seizures, or even coma in severe cases. Older adults are at higher risk.  \\n\\n3. **Hypomagnesemia (Low Magnesium)**:  \\n   - **Signs**: Muscle twitching, tremors, cramps, arrhythmias, or worsening hypokalemia (since Mg is needed for potassium regulation).  \\n\\n4. **Hypercalcemia (High Calcium)**:  \\n   - **Rare but possible**: Thiazides reduce urinary calcium excretion, which may cause elevated calcium levels. Watch for constipation, kidney stones, bone pain, or confusion.  \\n\\n### **Metabolic Changes**  \\n- **Hyperglycemia**: Thiazides can impair glucose tolerance, so monitor for increased thirst, frequent urination, or fatigue (signs of rising blood sugar).  \\n- **Hyperuricemia**: Gout flare-ups (joint pain, swelling) due to elevated uric acid.  \\n\\n### **Monitoring Recommendations**  \\n- Regular **blood tests** (electrolytes, renal function) early in treatment and periodically thereafter, especially in high-risk patients (e.g., elderly, those with CKD).  \\n- **Weight tracking**: Sudden drops may indicate dehydration.  \\n- **Symptom awareness**: Educate patients to report weakness, dizziness, or irregular heartbeats promptly.  \\n\\nWould you like additional details on management strategies (e.g., potassium-sparing add-ons, dietary adjustments)? I\\u2019m happy to dive deeper!","The specific active component commonly found in foot care creams designed to treat athlete&#x27;s foot (tinea pedis), especially for the interdigital (between the toes) fungal infections, is **clotrimazole** (1% concentration is typical). \\n\\n### Why Clotrimazole?  \\n- **Antifungal Action**: It disrupts fungal cell membranes by inhibiting ergosterol synthesis, which is essential for fungal growth.  \\n- **Broad-Spectrum**: Effective against dermatophytes like *Trichophyton rubrum*, the most common cause of athlete\\u2019s foot.  \\n- **Topical Efficacy**: Safe for skin application with minimal systemic absorption.  \\n\\n### Alternatives in Other Creams:  \\n- **Terbinafine (1%)**: Another potent antifungal, often used for resistant cases.  \\n- **Miconazole (2%)**: Works similarly to clotrimazole.  \\n- **Tolnaftate (1%)**: A non-imidazole antifungal, though less potent for severe infections.  \\n\\nWould you like details on application frequency or complementary treatments (e.g., keeping feet dry)?  \\n\\n*Note: Always check labels for the exact active ingredient, as formulations may vary by brand.*","The combination tablet of **Lisinopril and Hydrochlorothiazide** with **NDC 69097-969-07** has the following strength:  \\n\\n- **Lisinopril: 10 mg** (an ACE inhibitor for high blood pressure and heart failure)  \\n- **Hydrochlorothiazide: 12.5 mg** (a diuretic/\\"water pill\\" to help remove excess fluid)  \\n\\nThis is a commonly prescribed **10/12.5 mg** strength combination for hypertension management.  \\n\\nWould you like any additional details on usage, side effects, or alternatives? I\\u2019m happy to help!","The average terminal half-life of tapentadol following oral administration is approximately **4 hours** in healthy subjects with normal renal function.  \\n\\n### **Comparison in Subjects with Varying Renal Function:**  \\n1. **Normal Renal Function (Creatinine Clearance \\u226590 mL/min):**  \\n   - Half-life: ~4 hours  \\n2. **Mild Renal Impairment (CrCl 60\\u201389 mL/min):**  \\n   - Half-life: ~4.5 hours  \\n3. **Moderate Renal Impairment (CrCl 30\\u201359 mL/min):**  \\n   - Half-life: ~5\\u20136 hours  \\n4. **Severe Renal Impairment (CrCl &lt;30 mL/min or ESRD on dialysis):**  \\n   - Half-life: ~6\\u20137 hours (or longer if on dialysis)  \\n\\n**Key Observations:**  \\n- Tapentadol\\u2019s elimination is prolonged as renal function declines.  \\n- In severe renal impairment (including end-stage renal disease), the half-life increases significantly (up to ~7+ hours).  \\n- **Dosage adjustments** are recommended in moderate to severe renal impairment to avoid accumulation and toxicity.  \\n\\nWould you like any additional details on pharmacokinetics or dosing recommendations based on renal function?","Here\\u2019s a detailed breakdown of the **contraindications** and **potential effects** when **tizanidine** is used with **fluvoxamine** and **ciprofloxacin**:\\n\\n### **1. Contraindications &amp; Pharmacokinetic Interactions:**  \\n- **Tizanidine + Fluvoxamine (CYP1A2 inhibitor):**  \\n  - **Contraindication:** *Concomitant use is contraindicated* due to significantly increased plasma concentrations of tizanidine (up to **33-fold**), leading to severe hypotension and CNS depression.  \\n  - **Mechanism:** Fluvoxamine strongly inhibits **CYP1A2**, the primary enzyme metabolizing tizanidine.  \\n\\n- **Tizanidine + Ciprofloxacin (CYP1A2 inhibitor):**  \\n  - **Contraindication:** *Avoid concurrent use*\\u2014reduces tizanidine clearance by **10-15x**, heightening toxicity risks.  \\n  - **Mechanism:** Ciprofloxacin is a **moderate-to-strong CYP1A2 inhibitor**, prolonging tizanidine\\u2019s half-life.  \\n\\n- **Triple Combination (Tizanidine + Fluvoxamine + Ciprofloxacin):**  \\n  - **Absolute contraindication**\\u2014additive CYP1A2 inhibition drastically amplifies tizanidine levels, posing life-threatening risks.  \\n\\n### **2. Adverse Effects to Monitor:**  \\n#### **A. Blood Pressure:**  \\n- **Severe hypotension** (\\u2193 BP), syncope risk due to excessive **\\u03b1\\u2082-adrenergic agonism** (tizanidine\\u2019s effect).  \\n- Risk highest in the first **24-48 hours** of coadministration.  \\n\\n#### **B. Drowsiness &amp; CNS Depression:**  \\n- **Potentiated sedation** (fluvoxamine and ciprofloxacin both enhance GABAergic/central \\u03b1\\u2082 effects).  \\n- Risk of **respiratory depression** in vulnerable patients (e.g., elderly, COPD).  \\n\\n#### **C. Psychomotor Impairment:**  \\n- **Dangerously impaired alertness** (avoid driving/operating machinery).  \\n- **Delayed reaction times**\\u2014fluvoxamine alone can cause drowsiness; tizanidine compounds this.  \\n\\n### **3. Clinical Recommendations:**  \\n- **Alternative Agents:** Use non-CYP1A2-metabolized muscle relaxants (e.g., **baclofen**), or switch to non-interacting antibiotics (e.g., **azithromycin**).  \\n- **If Must Use:**  \\n  - **Tizanidine dose reduction by ~75-90%** (if no alternative).  \\n  - **Continuous BP/HR monitoring** (first 72h).  \\n  - **Patient Warning:** Emphasize fall risks, sedation, and avoiding alcohol.  \\n\\nThis combination is **high-risk**\\u2014extreme caution is mandatory. Always consult a pharmacist or prescriber before adjustments.  \\n\\nWould you like specific management protocols for adverse events (e.g., hypotension treatment)?","It looks like you&#x27;ve referenced an NDC (National Drug Code) number and are asking about the marketing start date for the corresponding product based on a provided document. However, I don&#x27;t have access to the document you mentioned, so I can&#x27;t retrieve the specific information about NDC:75990-4019-4. \\n\\nIf you can share the relevant details or excerpts from the document, I\\u2019d be happy to help extract and summarize the information for you. Alternatively, you could check the document&#x27;s FDA approval section, product label, or marketing history\\u2014those often contain official launch dates. Let me know how you&#x27;d like to proceed!","Great question! Candesartan cilexetil is an angiotensin II receptor blocker (ARB) used to treat hypertension and heart failure. Let&#x27;s break down the potential manifestations of overdose and the management of symptomatic hypotension.  \\n\\n### **Potential Manifestations of Overdosage**:  \\n1. **Hypotension**: Profound drop in blood pressure, leading to dizziness, syncope, or shock.  \\n2. **Bradycardia or Tachycardia**: Abnormal heart rhythms due to excessive vasodilation.  \\n3. **Renal Dysfunction**: Reduced kidney perfusion, potentially causing acute kidney injury (oliguria, elevated creatinine).  \\n4. **Electrolyte Imbalances**: Hyperkalemia (due to reduced aldosterone secretion).  \\n5. **Neurological Symptoms**: Weakness, confusion, or seizures (rare).  \\n\\n### **Supportive Treatment for Symptomatic Hypotension**:  \\n1. **Immediate Actions**:  \\n   - Place the patient in **Trendelenburg position** (legs elevated) to improve venous return.  \\n   - Administer **IV fluids** (e.g., normal saline) to restore intravascular volume.  \\n2. **Pharmacological Support**:  \\n   - **Vasopressors** (e.g., norepinephrine or dopamine) if hypotension persists despite fluids.  \\n   - **Atropine** (if significant bradycardia is present).  \\n3. **Monitoring &amp; Further Measures**:  \\n   - Continuous **ECG, BP, and renal function monitoring**.  \\n   - Hemodialysis is **not effective** (candesartan is highly protein-bound), but in severe cases, extracorporeal removal may be considered if refractory hypotension develops.  \\n4. **Other Considerations**:  \\n   - Correct electrolyte imbalances (e.g., hyperkalemia with calcium gluconate, insulin/glucose, or Kayexalate).  \\n   - If ingestion was recent (\\u22641-2 hrs), **activated charcoal** may be considered if the patient is alert and cooperative.  \\n\\nWould you like additional details on any of these aspects?","No response","No response","No response","No response"]],["reference_answer",["The strengths of hydrochlorothiazide in the candesartan cilexetil and hydrochlorothiazide tablets are 25 mg, 12.5 mg, and 12.5 mg for the different formulations.","NUCYNTA\\u2122 contains tapentadol, a mu-opioid agonist and is classified as a Schedule II controlled substance. It has an abuse potential similar to hydromorphone and can be abused, subject to criminal diversion.","Alcohol increased the AUC of tizanidine by approximately 20%, while also increasing its Cmax by approximately 15%. This was associated with an increase in side effects of tizanidine. The CNS depressant effects of tizanidine and alcohol are additive.","The active ingredient in the GRX DYNE povidone iodine solution is Povidone-Iodine.","The most frequent clinical adverse experiences reported in trials with lisinopril and hydrochlorothiazide tablets were dizziness (7.5%), headache (5.2%), cough (3.9%), fatigue (3.7%), and orthostatic effects (3.2%).","The medication tapentadol hydrochloride is available in strengths of 100 mg and 50 mg.","Hydrochlorothiazide is a diuretic and antihypertensive that affects the distal renal tubular mechanism of electrolyte reabsorption. It increases the excretion of sodium and chloride in approximately equivalent amounts.","Lisinopril and hydrochlorothiazide tablets are available in three combinations: 10 mg/12.5 mg, 20 mg/12.5 mg, and 20 mg/25 mg.","Tizanidine capsules and tizanidine tablets are bioequivalent to each other under fasting conditions, but not under fed conditions. When administered with food, the mean maximal plasma concentration for the capsule is approximately 66% the concentration for the tablet.","Aminotransferase levels should be monitored in patients taking tizanidine due to the risk of hepatocellular liver injury. Monitoring is recommended for baseline and 1 month after the maximum dose is achieved, or if hepatic injury is suspected.","The usual treatment for hypotension caused by an overdose of Lisinopril would be intravenous infusion of normal saline solution.","Candesartan inhibits the pressor effects of angiotensin II infusion in a dose-dependent manner. After 1 week of once-daily dosing with 8 mg of candesartan cilexetil, the pressor effect was inhibited by approximately 90% at peak with approximately 50% inhibition persisting for 24 hours.","The efficacy of NUCYNTA\\u2122 was evaluated in patients undergoing unilateral, first metatarsal bunionectomy surgery.","Some of the psychiatric disorders listed as adverse reactions to NUCYNTA\\u2122 include euphoric mood, disorientation, restlessness, agitation, nervousness, and abnormal thinking.","Some warning signs or symptoms of fluid and electrolyte imbalance that patients receiving thiazide therapy should be observed for include dryness of mouth, thirst, weakness, lethargy, drowsiness, restlessness, confusion, seizures, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea and vomiting.","The active ingredient in the foot care cream for athlete&#x27;s foot is butenafine hydrochloride 1%.","The Lisinopril and Hydrochlorothiazide tablets with NDC 69097-969-07 have a strength of 20 mg/12.5 mg.","The terminal half-life of tapentadol after oral administration is on average 4 hours.","The concomitant use of tizanidine with fluvoxamine and ciprofloxacin is contraindicated due to changes in the pharmacokinetics of tizanidine that result in significantly decreased blood pressure, increased drowsiness, and increased psychomotor impairment.","The marketing start date for the product with NDC:75990-4019-4 is 05/01/2011.","The most likely manifestations of overdosage with candesartan cilexetil would be hypotension, dizziness, and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.","The potential adverse effects on the fetus associated with the use of drugs that act on the renin-angiotensin system during pregnancy include reduced fetal renal function, increased fetal and neonatal morbidity and death, oligohydramnios, fetal lung hypoplasia, skeletal deformations, skull hypoplasia, anuria, hypotension, renal failure, and death.","The lisinopril in the tablets with NDC:69097-969 has a strength of 20 mg, while the hydrochlorothiazide has a strength of 12.5 mg.","The recommended dosing regimen for NUCYNTA (tapentadol) for the relief of moderate to severe acute pain is 50 mg, 75 mg, or 100 mg every 4 to 6 hours depending upon pain intensity. The second dose may be administered as soon as one hour after the first dose on the first day of dosing if adequate pain relief is not attained with the first dose.","Some of the nervous system disorders observed as adverse reactions during the premarketing evaluation of NUCYNTA\\u2122 include dizziness, somnolence, tremor, lethargy, insomnia, confusional state, abnormal dreams, anxiety, hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, depressed level of consciousness, memory impairment, ataxia, presyncope, syncope, coordination abnormal, and seizure."]],["id",[78,12,103,28,45,26,33,50,101,93,49,65,17,10,40,116,51,15,97,85,73,37,53,4,9]],["content",["Packaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:62559-661-90\\n90 \\nin 1 BOTTLE; Type 0: Not a Combination Product\\n09/26/2018\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nNDA authorized generic\\nNDA021093\\n09/26/2018\\nCANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE  \\ncandesartan cilexetil and hydrochlorothiazide tablet\\nProduct Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (So...","as for younger adult patients with normal renal and hepatic function. Because elderly patients are more\\nlikely to have decreased renal and hepatic function, consideration should be given to starting elderly\\npatients with the lower range of recommended doses \\n[see \\nClinical Pharmacology (12.3)\\n]\\n.\\n8.6 Renal Impairment\\nIn patients with severe renal impairment, the safety and effectiveness of NUCYNTA\\u2122 has not been\\nestablished. NUCYNTA\\u2122 is not recommended in this population \\n[see \\nDosage and Adminis...","this would be expected to lead to a longer duration of clinical effect. Tizanidine should be\\nused with caution in renally impaired patients \\n[see Warnings and Precautions ( \\n5.7\\n) and\\nUse in Specific Populations ( \\n8.6\\n)] \\n.\\nGender Effects\\nNo specific pharmacokinetic study was conducted to investigate gender effects.\\nRetrospective analysis of pharmacokinetic data, however, following single and multiple\\ndose administration of 4 mg Tizanidine showed that gender had no effect on the\\npharmacokinetic...","Citric acid, glycerin, Nonoxynol 10, purified water, sodium hydroxide\\nStore at room temperature: 15&#x27;-30&#x27;C (59&#x27;-86&#x27;F)\\nkeep out of reach of children. If swallowed get medical help \\nor contact a Poison Control Center right away.\\nEnter section text here\\nGRX DYNE  \\npovidone iodine solution\\nProduct Information\\nProduct Type\\nHUMAN OTC DRUG\\nItem Code (Source)\\nNDC:54162-269\\nRoute of Administration\\nTOPICAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nPOVIDONE-IODINE\\n (UNII: 85...","Nursing Mothers\\nIt is not known whether lisinopril is excreted in human milk. However, milk of lactating\\nrats contains radioactivity following administration of \\nC lisinopril. In another study,\\nlisinopril was present in rat milk at levels similar to plasma levels in the dams. Thiazides\\ndo appear in human milk. Because of the potential for serious adverse reactions in\\nnursing infants from ACE inhibitors and hydrochlorothiazide, a decision should be made\\nwhether to discontinue nursing and/or disco...","Stat Rx USA\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\ntapentadol hydrochloride\\n (UNII: 71204KII53) \\n(tapentadol - UNII:H8A007M585)\\ntapentadol\\n100 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\ncellulose, microcrystalline\\n (UNII: OP1R32D61U)\\n \\nlactose monohydrate\\n (UNII: EWQ57Q8I5X)\\n \\ncroscarmellose sodium\\n (UNII: M28OL1HH48)\\n \\npovidone\\n (UNII: FZ989GH94E)\\n \\nmagnesium stearate\\n (UNII: 70097M6I30)\\n \\npolyvinyl alcohol\\n (UNII: 532B59J990)\\n \\ntitanium dioxide\\n (UNII:...","state is prolonged. Older patients, on average, have (approximately doubled) higher\\nblood levels and area under the plasma concentration time curve (AUC) than younger\\npatients (see \\nDOSAGE AND ADMINISTRATION\\n). In a multiple dose pharmacokinetic study\\nin elderly versus young hypertensive patients using the lisinopril/hydrochlorothiazide\\ncombination, the AUC increased approximately 120% for lisinopril and approximately\\n80% for hydrochlorothiazide in older patients. Lisinopril can be removed by\\nhe...","possible, be discontinued for two to three days before beginning therapy with lisinopril\\nto reduce the likelihood of hypotension (See \\nWARNINGS\\n). If the patient\\u2019s blood pressure\\nis not controlled with lisinopril alone, diuretic therapy may be resumed.\\nIf the diuretic cannot be discontinued, an initial dose of 5 mg of lisinopril should be used\\nunder medical supervision for at least two hours and until blood pressure has stabilized\\nfor at least an additional hour (See \\nWARNINGS\\n and \\nPRECAUTIONS\\n...","12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\nTizanidine is a central alpha-2-adrenergic receptor agonist and presumably reduces\\nspasticity by increasing presynaptic inhibition of motor neurons. The effects of tizanidine\\nare greatest on polysynaptic pathways. The overall effect of these actions is thought to\\nreduce facilitation of spinal motor neurons.\\n12.3 Pharmacokinetics\\nAbsorption and Distribution\\nFollowing oral administration, tizanidine is essentially completely absorbed. The absolute\\n...","Tizanidine is an \\u03b1 \\n-adrenergic agonist that can produce hypotension. Syncope has been\\nreported in the post marketing setting. The chance of significant hypotension may\\npossibly be minimized by titration of the dose and by focusing attention on signs and\\nsymptoms of hypotension prior to dose advancement. In addition, patients moving from\\na supine to fixed upright position may be at increased risk for hypotension and\\northostatic effects.\\nMonitor for hypotension when tizanidine is used in patients...","Lisinopril\\n \\nFollowing a single oral dose of 20 g/kg no lethality occurred in rats and death occurred in\\none of 20 mice receiving the same dose. The most likely manifestation of overdosage\\nwould be hypotension, for which the usual treatment would be intravenous infusion of\\nnormal saline solution.\\nLisinopril can be removed by hemodialysis (see \\nWARNINGS, Anaphylactoid Reaction\\nDuring Membrane Exposure\\n).\\nHydrochlorothiazide\\n \\nOral administration of a single oral dose of 10 g/kg to mice and rats w...","Geriatric\\nThe pharmacokinetics of candesartan have been studied in the elderly (\\u2265 65 years). \\nThe plasma\\nconcentration of candesartan was higher in the elderly (C\\n was approximately 50% higher, and AUC\\nwas approximately 80% higher) compared to younger subjects administered the same dose. \\nThe\\npharmacokinetics of candesartan were linear in the elderly, and candesartan and its inactive metabolite\\ndid not accumulate in the serum of these subjects upon repeated, once-daily administration. \\nNo initia...","14 CLINICAL STUDIES\\nThe efficacy and safety of NUCYNTA\\u2122 in the treatment of moderate to severe acute pain has been\\nestablished in two randomized, double-blind, placebo- and active-controlled studies of moderate to\\nsevere pain from first metatarsal bunionectomy and end-stage degenerative joint disease.\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\nA randomized, double-blind, parallel-group, active- and placebo-controlled, multiple-dose study\\ndemonstrated the efficacy of 50 mg, 75 mg, and 100 mg NUCYNTA\\u2122...","Psychiatric disorders:\\n euphoric mood, disorientation, restlessness, agitation, nervousness, thinking\\nabnormal\\nRenal and urinary disorders:\\n urinary hesitation, pollakiuria\\nRespiratory, thoracic and mediastinal disorders: \\noxygen saturation decreased, cough, dyspnea,\\nrespiratory depression\\nSkin and subcutaneous tissue disorders: \\nurticaria\\nVascular disorders:\\n blood pressure decreased\\nIn the pooled safety data, the overall incidence of adverse reactions increased with increased dose of\\nNUCYNTA\\u2122,...","be due to this mechanism, it can be corrected by volume expansion.\\nHydrochlorothiazide\\n \\nPeriodic determination of serum electrolytes to detect possible electrolyte imbalance\\nshould be performed at appropriate intervals.\\nAll patients receiving thiazide therapy should be observed for clinical signs of fluid or\\nelectrolyte imbalance: namely, hyponatremia, hypochloremic alkalosis, and hypokalemia.\\nSerum and urine electrolyte determinations are particularly important when the patient is\\nvomiting exc...","RITE \\nAID \\n \\nPHARMACY\\nclinically proven to cure \\nmost athlete&#x27;s foot between the toes\\nfoot care \\nbutenafine\\nhydrochloride cream 1%\\nantifungal\\nNET WT 0.42 OZ (12 g)\\n\\u00ae","Protect from excessive light and humidity.\\n*AN69 is a registered trademark of Hospal Ltd.\\nManufactured by:\\nInvaGen Pharmaceuticals, Inc.\\n(a subsidiary of Cipla Ltd.)\\nHauppauge, NY 11788\\nManufactured for:\\nCipla USA, Inc.\\n10 Independence Boulevard, Suite 300\\nWarren, NJ 07059\\nRevised: 10/2021\\nPACKAGE/LABEL PRINCIPAL DISPLAY PANEL \\u2013 10 mg/12.5 mg\\nNDC 69097-968-07                      Rx Only\\nLisinopril and\\nHydrochlorothiazide\\nTablets, USP\\n10 mg/12.5 mg\\n100 Tablets\\nCipla\\nNDC 69097-969-07             ...","extensive first-pass metabolism. Maximum serum concentrations of tapentadol are typically observed at\\naround 1.25 hours after dosing.\\nDose-proportional increases in the C\\n and AUC values of tapentadol have been observed over the 50\\nto 150 mg dose range.\\nA multiple (every 6 hour) dose study with doses ranging from 75 to 175 mg tapentadol showed a mean\\naccumulation factor of 1.6 for the parent drug and 1.8 for the major metabolite tapentadol-O-\\nglucuronide, which are primarily determined by the do...","Paresthesia\\nRash\\nTremor\\n7 DRUG INTERACTIONS\\n7.1 Fluvoxamine\\nConcomitant use of fluvoxamine and tizanidine is contraindicated. Changes in\\npharmacokinetics of tizanidine when administered with fluvoxamine resulted in\\nsignificantly decreased blood pressure, increased drowsiness, and increased\\npsychomotor impairment. \\n[see Contraindications ( \\n4\\n) and Clinical Pharmacology ( \\n12.3\\n)]\\n7.2 Ciprofloxacin\\nConcomitant use of ciprofloxacin and tizanidine is contraindicated. Changes in\\npharmacokinetics of ...","Certus Medical, Inc.\\nWATER\\n (UNII: 059QF0KO0R)\\n \\nGLYCERIN\\n (UNII: PDC6A3C0OX)\\n \\nSODIUM PHOSPHATE, DIBASIC\\n (UNII: GR686LBA74)\\n \\nNONOXYNOL-10\\n (UNII: K7O76887AP)\\n \\nDIMETHICONE\\n (UNII: 92RU3N3Y1O)\\n \\nHYDROXYETHYL CELLULOSE (2000 CPS AT 1%)\\n (UNII: S38J6RZN16)\\n \\nPackaging\\n#\\nItem Code\\nPackage Description\\nMarketing Start Date\\nMarketing End Date\\n1\\nNDC:75990-4019-4\\n2 mL in 1 POUCH\\nMarketing Information\\nMarketing Category\\nApplication Number or Monograph Citation\\nMarketing Start Date\\nMarketing End Date\\nOT...","melanoma skin cancer. In a study conducted in the Sentinel System, increased risk was predominantly for\\nsquamous cell carcinoma (SCC) and in white patients taking large cumulative doses. The increased risk\\nfor SCC in the overall population was approximately 1 additional case per 16,000 patients per year, and\\nfor white patients taking a cumulative dose of \\u226550,000 mg the risk increase was approximately 1\\nadditional SCC case for every 6,700 patients per year.\\nSkin:\\n \\nerythema multiforme including S...","myocardial infarction or cerebrovascular accident.\\nIf hypotension occurs, the patient should be placed in the supine position and, if\\nnecessary, receive an intravenous infusion of normal saline. A transient hypotensive\\nresponse is not a contraindication to further doses which usually can be given without\\ndifficulty once the blood pressure has increased after volume expansion.\\nLeukopenia/Neutropenia/Agranulocytosis:\\n Another angiotensin-converting enzyme\\ninhibitor, captopril, has been shown to ca...","Product Information\\nProduct Type\\nHUMAN PRESCRIPTION DRUG\\nItem Code (Source)\\nNDC:69097-968\\nRoute of Administration\\nORAL\\nActive Ingredient/Active Moiety\\nIngredient Name\\nBasis of Strength\\nStrength\\nLISINOPRIL\\n (UNII: E7199S1YWR) \\n(LISINOPRIL ANHYDROUS - UNII:7Q3P4BS2FD)\\nLISINOPRIL\\n10 mg\\nHYDROCHLOROTHIAZIDE\\n (UNII: 0J48LPH2TH) \\n(HYDROCHLOROTHIAZIDE -\\nUNII:0J48LPH2TH)\\nHYDROCHLOROTHIAZIDE\\n12.5 mg\\nInactive Ingredients\\nIngredient Name\\nStrength\\nANHYDROUS DIBASIC CALCIUM PHOSPHATE\\n (UNII: L11K75P92J)\\n \\nMAN...","8.7 Hepatic Impairment\\n9 DRUG ABUSE AND DEPENDENCE\\n9.1 Controlled Substance\\n9.2 Abuse\\n9.3 Dependence\\n10 OVERDOSAGE\\n10.1 Human Experience\\n10.2 Management of Overdose\\n11 DESCRIPTION\\n12 CLINICAL PHARMACOLOGY\\n12.1 Mechanism of Action\\n12.2 Pharmacodynamics\\n12.3 Pharmacokinetics\\n13 NON-CLINICAL TOXICOLOGY\\n13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility\\n13.2 Animal Toxicology and/or Pharmacology\\n14 CLINICAL STUDIES\\n14.1 Orthopedic Surgery \\u2013 Bunionectomy\\n14.2 End-Stage Degenerative Joint Disea...","*\\nInfections and infestations\\n  Nasopharyngitis\\n1\\n&lt;1\\n  Upper respiratory tract infection\\n1\\n&lt;1\\n  Urinary tract infection\\n1\\n&lt;1\\nMetabolism and nutrition disorders\\n  Decreased appetite\\n2\\n0\\nMusculoskeletal and connective tissue\\ndisorders\\n  Arthralgia\\n1\\n&lt;1\\nNervous system disorders\\n  Dizziness\\n24\\n8\\n  Somnolence\\n15\\n3\\n  Tremor\\n1\\n&lt;1\\n  Lethargy\\n1\\n&lt;1\\nPsychiatric disorders\\n  Insomnia\\n2\\n&lt;1\\n  Confusional state\\n1\\n0\\n  Abnormal dreams\\n1\\n&lt;1\\n  Anxiety\\n1\\n&lt;1\\nSkin and subcutaneous tissue disorders\\n  Pruritus\\n5\\n1\\n  Hyp..."]],["color",["#ba0e0e","#ba0e0e","#0a980a","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#0a980a","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e","#ba0e0e"]]]}}},"view":{"type":"object","name":"CDSView","id":"p1831","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1832"}}},"glyph":{"type":"object","name":"Scatter","id":"p1827","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.7},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.7}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1828","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.1},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1829","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"field","field":"color"},"line_alpha":{"type":"value","value":0.2},"line_width":{"type":"value","value":2},"fill_color":{"type":"field","field":"color"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"field","field":"color"},"hatch_alpha":{"type":"value","value":0.2}}}}},{"type":"object","name":"GlyphRenderer","id":"p1845","attributes":{"data_source":{"type":"object","name":"ColumnDataSource","id":"p1836","attributes":{"selected":{"type":"object","name":"Selection","id":"p1837","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1838"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"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"},"shape":[117],"dtype":"float32","order":"little"}]]}}},"view":{"type":"object","name":"CDSView","id":"p1846","attributes":{"filter":{"type":"object","name":"AllIndices","id":"p1847"}}},"glyph":{"type":"object","name":"Scatter","id":"p1842","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}},"nonselection_glyph":{"type":"object","name":"Scatter","id":"p1843","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.1},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.1},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.1}}},"muted_glyph":{"type":"object","name":"Scatter","id":"p1844","attributes":{"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"size":{"type":"value","value":6},"line_color":{"type":"value","value":"grey"},"line_alpha":{"type":"value","value":0.2},"fill_color":{"type":"value","value":"grey"},"fill_alpha":{"type":"value","value":0.2},"hatch_color":{"type":"value","value":"grey"},"hatch_alpha":{"type":"value","value":0.2}}}}}],"toolbar":{"type":"object","name":"Toolbar","id":"p1799","attributes":{"logo":"grey","tools":[{"type":"object","name":"PanTool","id":"p1814"},{"type":"object","name":"WheelZoomTool","id":"p1815","attributes":{"renderers":"auto"}},{"type":"object","name":"BoxZoomTool","id":"p1816","attributes":{"overlay":{"type":"object","name":"BoxAnnotation","id":"p1817","attributes":{"syncable":false,"level":"overlay","visible":false,"left":{"type":"number","value":"nan"},"right":{"type":"number","value":"nan"},"top":{"type":"number","value":"nan"},"bottom":{"type":"number","value":"nan"},"left_units":"canvas","right_units":"canvas","top_units":"canvas","bottom_units":"canvas","line_color":"black","line_alpha":1.0,"line_width":2,"line_dash":[4,4],"fill_color":"lightgrey","fill_alpha":0.5}}}},{"type":"object","name":"ResetTool","id":"p1822"},{"type":"object","name":"SaveTool","id":"p1823"},{"type":"object","name":"HoverTool","id":"p1790","attributes":{"renderers":[{"id":"p1830"}],"tooltips":"\\n    &lt;div style=\\"width:400px;\\"&gt;\\n    &lt;b&gt;Document id:&lt;/b&gt; @id &lt;br&gt;\\n    &lt;b&gt;Topic:&lt;/b&gt; @topic &lt;br&gt;\\n    &lt;b&gt;Question:&lt;/b&gt; @questions &lt;br&gt;\\n    &lt;b&gt;agent Answer:&lt;/b&gt; @agent_answer &lt;br&gt;\\n    &lt;b&gt;Reference Answer:&lt;/b&gt; @reference_answer &lt;br&gt;\\n    &lt;b&gt;Correctness:&lt;/b&gt; @correctness &lt;br&gt;\\n    &lt;b&gt;Content:&lt;/b&gt; @content\\n    &lt;/div&gt;\\n    "}}]}},"left":[{"type":"object","name":"LinearAxis","id":"p1809","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1810","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1811"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1812"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"below":[{"type":"object","name":"LinearAxis","id":"p1804","attributes":{"ticker":{"type":"object","name":"BasicTicker","id":"p1805","attributes":{"mantissas":[1,2,5]}},"formatter":{"type":"object","name":"BasicTickFormatter","id":"p1806"},"axis_label_standoff":10,"axis_label_text_color":"#E0E0E0","axis_label_text_font":"Helvetica","axis_label_text_font_size":"1.25em","axis_label_text_font_style":"normal","major_label_policy":{"type":"object","name":"AllLabels","id":"p1807"},"major_label_text_color":"#E0E0E0","major_label_text_font":"Helvetica","major_label_text_font_size":"1.025em","axis_line_color":"#E0E0E0","axis_line_alpha":0,"major_tick_line_color":"#E0E0E0","major_tick_line_alpha":0,"minor_tick_line_color":"#E0E0E0","minor_tick_line_alpha":0}}],"center":[{"type":"object","name":"Grid","id":"p1808","attributes":{"axis":{"id":"p1804"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Grid","id":"p1813","attributes":{"dimension":1,"axis":{"id":"p1809"},"grid_line_color":"white","grid_line_alpha":0.25}},{"type":"object","name":"Legend","id":"p1833","attributes":{"title":"Question Correctness","title_text_color":"#B1B1B1","title_text_font_style":"bold","border_line_alpha":0,"background_fill_color":"#111516","background_fill_alpha":0.5,"label_text_color":"#E0E0E0","label_text_font":"Helvetica","label_text_font_size":"1.025em","label_standoff":8,"glyph_width":15,"spacing":8,"items":[{"type":"object","name":"LegendItem","id":"p1834","attributes":{"label":{"type":"value","value":"False"},"renderers":[{"id":"p1830"}],"index":0}},{"type":"object","name":"LegendItem","id":"p1835","attributes":{"label":{"type":"value","value":"True"},"renderers":[{"id":"p1830"}],"index":2}}]}},{"type":"object","name":"LabelSet","id":"p1851","attributes":{"level":"glyph","source":{"type":"object","name":"ColumnDataSource","id":"p1848","attributes":{"selected":{"type":"object","name":"Selection","id":"p1849","attributes":{"indices":[],"line_indices":[]}},"selection_policy":{"type":"object","name":"UnionRenderers","id":"p1850"},"data":{"type":"map","entries":[["x",{"type":"ndarray","array":{"type":"bytes","data":"qqUxQWZoDUEzPX5At+fuQL+gmEA="},"shape":[5],"dtype":"float32","order":"little"}],["y",{"type":"ndarray","array":{"type":"bytes","data":"LG+OQRTcmkFHb49BHSaFQam0ekE="},"shape":[5],"dtype":"float32","order":"little"}],["topic",["Tizanidine Overdose","Medication Information","ACE Inhibitors","Pharmaceutical Products","Candesartan Cilexetil"]]]}}},"x":{"type":"field","field":"x"},"y":{"type":"field","field":"y"},"text":{"type":"field","field":"topic"},"text_color":{"type":"value","value":"#B1B1B1"},"text_font_size":{"type":"value","value":"12pt"},"text_font_style":{"type":"value","value":"bold"},"text_align":{"type":"value","value":"center"}}}],"background_fill_color":"#14191B","border_fill_color":"#15191C"}}}}],"tabs_location":"below"}}]}}';
        const render_items = [{"docid":"c19a263b-e8a0-4fe8-9504-ab9ec59e8ea7","roots":{"p1856":"ba2aa1a6-559b-4d05-96fa-3b1ffce0787a"},"root_ids":["p1856"]}];
        root.Bokeh.embed.embed_items(docs_json, render_items);
        }
        if (root.Bokeh !== undefined) {
          embed_document(root);
        } else {
          let attempts = 0;
          const timer = setInterval(function(root) {
            if (root.Bokeh !== undefined) {
              clearInterval(timer);
              embed_document(root);
            } else {
              attempts++;
              if (attempts > 100) {
                clearInterval(timer);
                console.log("Bokeh: ERROR: Unable to run BokehJS code because BokehJS library is missing");
              }
            }
          }, 10, root)
        }
      })(window);
    });
  };
  if (document.readyState != "loading") fn();
  else document.addEventListener("DOMContentLoaded", fn);
})();
    </script>

                <div id="ba2aa1a6-559b-4d05-96fa-3b1ffce0787a" data-root-id="p1856" style="display: contents;"></div>
            </div>
        </div>

        <div class="section-container">
            <div class="section-card">

                <div class="section-title">SELECTED METRICS</div>

                

            </div>
        </div>

        
    </div>
</div>



<script type="text/javascript">
    function opentab(evt, name) {
    // Declare all variables
    let i, tabcontent, tablinks;

    // Get all elements with class="tabcontent" and hide them
    tabcontent = document.getElementsByClassName("tabcontent");
    for (i = 0; i < tabcontent.length; i++) {
        tabcontent[i].style.display = "none";
    }

    // Get all elements with class="tablinks" and remove the class "active"
    tablinks = document.getElementsByClassName("tablinks");
    for (i = 0; i < tablinks.length; i++) {
        tablinks[i].className = tablinks[i].className.replace(" active", "");
    }

    // Show the current tab, and add an "active" class to the button that opened the tab
    document.getElementById(name).style.display = "block";
    evt.currentTarget.className += " active";
}
</script>
